University of Mississippi

eGrove
Electronic Theses and Dissertations

Graduate School

1-1-2012

Pharmaceutical formulation development utilizing hot melt
extrusion and other techniques for development of immediate
and controlled release dosage forms
Noorullah Naqvi Mohammed
University of Mississippi

Follow this and additional works at: https://egrove.olemiss.edu/etd
Part of the Pharmacy and Pharmaceutical Sciences Commons

Recommended Citation
Mohammed, Noorullah Naqvi, "Pharmaceutical formulation development utilizing hot melt extrusion and
other techniques for development of immediate and controlled release dosage forms" (2012). Electronic
Theses and Dissertations. 1485.
https://egrove.olemiss.edu/etd/1485

This Dissertation is brought to you for free and open access by the Graduate School at eGrove. It has been
accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of eGrove. For more
information, please contact egrove@olemiss.edu.

PHARMACEUTICAL FORMULATION DEVELOPMENT UTILIZING HOT MELT
EXTRUSION AND OTHER TECHNIQUES FOR DEVELOPMENT OF IMMEDIATE AND
CONTROLLED RELEASE DOSAGE FORMS

A Dissertation
Presented for the
Doctor of Philosophy
Degree
The University of Mississippi

by
MOHAMMED NOORULLAH NAQVI
May 2012

Copyright© ------ by Mohammed Noorullah Naqvi
All rights reserved

ABSTRACT
Hot melt extrusion (HME) was evaluated as a processing technology for the manufacture
of immediate as well as controlled release formulations for oral delivery of two model
compounds. For immediate release applications lower molecular weight grades of
Hydroxypropyl cellulose polymers, EF and ELF, were utilized as carrier matrices to form solid
solutions of a poorly soluble compound, Ketoprofen (KPR). Thermal characterization techniques
were used to confirm thermal stability, miscibility and setting up processing conditions for
extrusion. Extruded matrices were pelletized to be filled into pellets or further milled and
compressed into tablets. Pellets exhibited a carrier dependent release with ELF matrices
releasing the drug at a faster rate than EF. Addition of Mannitol further enhanced the release
with H4 formulation constituting KPR:MNT:ELF in a 1:1:1, releasing 88.5±1.5% drug in 1hr.
Milled H4 matrices compressed into tablets exhibited rapid release with 90% drug release
occurring in 15 min, similar to a marketed capsule formulation of the same dose. Stability studies
performed utilizing mDSC, XRD and SEM studies confirmed the physical stability of the drug,
post storage at 25°C/60%RH and 40°C/75%RH.
Extrusion process also imparts significant physical transformations to the component
systems which find utility in tabletting applications. Extruded matrices were compressed into
tablets and tabletability profiles generated. Simultaneously tablet hardness evaluation was
performed using conventional characterization techniques as well as using a texture analyzer.
ii

HME tablets were more compressible and plastic nature in comparison to un-extruded tablets.
ELF polymers exhibited better tabletting properties than EF.
The ability of HME to homogenously mix polymers and drug was utilized to manufacture
custom controlled release film formulations of a water soluble model drug. Polymer blends
comprising Klucel™ EF (HPC), Eudragit® RSPO and POLYOX® N10 (PEO) were evaluated.
Effect of polymer particle size on release was evaluated using in vitro release testing and Near
Infrared chemical imaging techniques. Manufactured films exhibited controlled release for
~24 hrs with HPC exhibiting a more pronounced effect than RSPO. A correlation of 90% was
obtained between polymer concentration on fifty percent and eighty percent drug release, T50%
and T80%, respectively, suggesting its applicability to bring about tailored release profiles.
Extruded films remained physically and chemically stable for a period of three months at
40°C/75%RH storage conditions.
The ability of Cyclodextrin derivatives to enhance solubility of a poorly soluble drug,
Clotrimazole was evaluated. Phase solubility studies were performed to assess the type of
association between CT and 2-hydroxypropyl β Cyclodextrin. An AL type curve was obtained
suggesting a 1:1 association, which was further confirmed utilizing DSC, FTIR, XRD, NMR and
SEM analysis. Gels formulated from complex exhibited a complete release in 92 hrs whereas
pure CT gels exhibited only 60% release in the same amount of time. Similar results were
obtained with antifungal testing, with complexed gels having a more pronounced fungistatic
action.

iii

DEDICATION
Dedicated to my parents Mr. Mohammed Rafi and Mrs. Sheik Rameeza, Brother-Mohammed
Abdul Habeeb, Sister- Mubina Parveen and
To my lovely wife Nayaab Khan for all their support, encouragement and affection all through
these years.

iv

ACKNOWLEDGEMENTS
I would like to express my deepest gratitude, appreciation and thanks to my advisor Dr.
Michael A. Repka, Chair, Dept. of Pharmaceutics for his support and guidance during my PhD.
He has always encouraged me and assigned me projects that were thoroughly intriguing and
insightful.
I would also like to thank Dr. Seongbong Jo, Dr. John S. Williamson and Dr. Soumyajit
Majumdar, for their valuable advice, suggestions and for serving on my dissertation committee.
My special thanks to Dr. Majumdar for his advice with research projects and endearing support.
I would also like to acknowledge the help rendered to me by Dr. Bonnie Avery, Dr.
Narasimha Murthy, Miss Deborah King and the graduate students of pharmaceutics department.
To members of Dr. Repka’s group, for all those memorable moments in labs112A and B.
I thank Dr. Ziyaur Rahman, a research scholar who initially trained me, for his help with
chemical imaging and providing me with a critical review of my work. Dr. Vijay and Dr. Melissa
Jacobs for their help with SEM analysis and antifungal assay. Dr. Waseem Gul, for his help with
NMR and IR analysis. Dr. Siddharthya Mujumdar, Boehringer Ingelheim, for presenting me with
an opportunity to work with him as an intern and acquire skills that have helped me with my
dissertation work.

v

I am thankful and privileged to have the support and love of my beloved parents Mr.
Mohammed Rafi and Mrs. Sheik Rameeza, sister (Mubina Parveen) and brother (Mohammed
Abdul Habeeb). I am fortunate to have the support of very understanding, encouraging in-laws
and greatly appreciate their help all along. Special thanks to my brother in law Mr. Mohammad
Khaja Fariduddin for standing by me and supporting me during time of need.
My lovely wife, Nayaab Khan for her patience, understanding and being an integral
support structure during the many ups downs of a Ph.D in a foreign country. I owe it to all of
them and greatly appreciate the help rendered to me on a personal as well as on a professional
front.

vi

TABLE OF CONTENTS
ABSTRACT .................................................................................................................................... ii
DEDICATION ............................................................................................................................... iv
ACKNOWLEDGEMENTS ............................................................................................................ v
TABLE OF CONTENTS .............................................................................................................. vii
LIST OF TABLES ....................................................................................................................... xvi
LIST OF FIGURES .................................................................................................................... xvii
CHAPTER I .................................................................................................................................... 1
INTRODUCTION .......................................................................................................................... 1
1.1. Solid Dispersions and Solid Solutions ..................................................................................... 3
1.1.1. Advantages and Disadvantages Solid dispersions ............................................................ 4
1.1.2. Manufacturing Methods .................................................................................................... 5
1.2. Hot Melt Extrusion .............................................................................................................. 7
1.2.1. Types of Extrusion Process ........................................................................................... 8
1.2.2. Schematics and Components of a Hot Melt Extruder................................................... 8
1.2.3. Screw based Extruder ................................................................................................... 9
1.2.3.1. Driving motor......................................................................................................... 9

vii

1.2.3.2. Barrel.................................................................................................................... 10
1.2.3.3. Screw Elements .................................................................................................... 11
1.2.3.4. Twin screw extruders (TSE) ................................................................................ 13
1.2.3.5. Discharge and Post Processing Equipment .......................................................... 14
1.2.4. Carriers and Processing Aids ...................................................................................... 15
1.2.4.1. Carrier materials................................................................................................... 16
1.2.4.2. Processing Aids .................................................................................................... 20
1.2.5. Pharmaceutical Applications of Hot Melt Extrusion .................................................. 22
1.3. Cyclodextrins ..................................................................................................................... 24
1.3.1. Mechanism of Inclusion complex formation .............................................................. 25
1.3.2. Method of Manufacture of CD complexes ................................................................. 27
1.3.3 Applications of CD complexation ............................................................................... 29
CHAPTER II
Objectives and Model Drugs ........................................................................................................ 31
2.1. Applicability and advantages of HME for solubility enhancement and as a processing tool
for capsule and tablet formulations using Klucel™ EF and ELF polymers ............................. 31
2.1.1. Objectives ................................................................................................................... 31
2.1.2. Model Drug - Ketoprofen ........................................................................................... 32
2.2. Formulation of controlled release film formulations utilizing polymers blends for water
soluble drug via hot melt extrusion........................................................................................... 33

viii

2.2.1. Objectives ................................................................................................................... 33
2.2.2. Model Drug - Chlorpheniramine Maleate................................................................... 34
2.3. Clotrimazole-Cyclodextrin complex for treatment of vaginal candidiasis ........................ 35
2.3.1. Objectives ................................................................................................................... 35
2.3.2. Model Drug – Clotrimazole ........................................................................................ 36
CHAPTER III
Applicability and Advantages of HME for Solubility Enhancement and as a Processing Tool
for Capsule and Tablet Formulations Using Klucel™ EF and ELF Polymers ......................... 37
3.1. ABSTRACT ....................................................................................................................... 37
3.2. Introduction ........................................................................................................................ 38
3.3. Materials ............................................................................................................................ 40
3.4. Methods.............................................................................................................................. 41
3.4.1. Thermal Characterization Studies ................................................................................... 41
3.4.1.1. Thermogravimetric Analysis ................................................................................... 41
3.4.1.2. Differential Scanning Colorimetry .......................................................................... 41
3.4.1.3. Hot stage microscopy............................................................................................... 42
3.4.1.4. Solubility parameters ............................................................................................... 42
3.4.2. HPLC Method ............................................................................................................. 43
3.4.3. Formulation – .................................................................................................................. 43
3.4.3.1 Formulation composition and HME processing ....................................................... 43

ix

3.4.3.2. Tabletting ................................................................................................................. 45
3.4.4. Evaluation of Extruded system- Pellets and Tablets....................................................... 47
3.4.4.1. Moisture absorption studies ..................................................................................... 47
3.4.4.2. Microscopy studies .................................................................................................. 47
3.4.4.3. In Vitro Release Studies ........................................................................................... 48
3.4.4.4. Powder X-ray diffraction ......................................................................................... 48
3.4.5. Stability testing ........................................................................................................... 49
3.5. RESULTS AND DISCUSSION ........................................................................................ 50
3.5.1. Thermal Characterization............................................................................................ 50
3.5.1.1. Thermo Gravimetric analysis ................................................................................... 50
3.5.1.2. Hot Stage Microscopy.............................................................................................. 51
3.5.1.3. Miscibility Studies ................................................................................................... 52
3.5.1.4. Solubility parameters ............................................................................................... 54
3.5.2. Hot melt Extrusion Process ......................................................................................... 54
3.5.3. Evaluation of Pellets ................................................................................................... 57
3.5.3.1. Moisture Absorption Studies ................................................................................... 57
3.5.3.2. Polarized light microscopy of Extrudates ................................................................ 59
3.5.3.3. Scanning Electron Microscope ................................................................................ 60
3.5.3.4. Differential Scanning Calorimetry studies............................................................... 60
3.5.4. In Vitro Release Studies .............................................................................................. 62
x

3.5.4.1. In Vitro release studies - Pellets ............................................................................... 62
3.5.4.2. Effect of Drug loading ............................................................................................. 65
3.5.4.3. SEM evaluation of pellets at different drug loading ................................................ 69
3.5.4.4. In Vitro release studies – Tablets ............................................................................. 71
3.6. Stability Testing –Pellets and Tablets ............................................................................ 74
CONCLUSION ......................................................................................................................... 78
CHAPTER - IV
Characterization of Tabletting Behavior of Blends Manufactured From Hot Melt Extruded
Matrices......................................................................................................................................... 79
Abstract ..................................................................................................................................... 79
4.1. Introduction ........................................................................................................................ 80
4.2. Materials and Methods ....................................................................................................... 81
4.2.1. Excipient compatibility studies ................................................................................... 82
4.2.2. Tablet characterization ................................................................................................ 82
4.2.3. Compaction profiles .................................................................................................... 83
4.2.4. Texture analyzer.......................................................................................................... 83
4.3. RESULT AND DISCUSSION .......................................................................................... 85
4.3.1. Tablet – Excipient Compatibility studies .................................................................... 85
4.3.2. Compactibility Profiles ............................................................................................... 87
4.3.3. Tablet characterization tests ........................................................................................ 91

xi

4.3.3. Hardness evaluation utilizing Texture analyzer .......................................................... 93
CONCLUSION ......................................................................................................................... 95
CHAPTER V
Custom – Controlled Release Formulations Utilizing Polymer Blends And Hot Melt Extrusion
For A Water Soluble Drug ............................................................................................................ 96
5.1. Abstract .............................................................................................................................. 96
5.2. Introduction ........................................................................................................................ 97
5.3. Materials ............................................................................................................................ 99
5.4. Methods............................................................................................................................ 100
5.4.1. Thermal Characterization.......................................................................................... 100
5.4.2. Solubility parameters ................................................................................................ 101
5.4.3. Formulation Composition ......................................................................................... 102
5.4.4. Hot Melt Casting method for films ........................................................................... 103
5.4.5. Hot Melt Extrusion ................................................................................................... 103
5.4.6. HPLC analysis .......................................................................................................... 103
5.4.7. Particle Size Distribution of Polymers ...................................................................... 104
5.4.8. Near Infrared Chemical Imaging spectroscopy ........................................................ 104
5.4.9.1. In vitro Release studies and Release mechanisms ................................................. 105
5.4.9.2. Statistical analysis .............................................................................................. 106
5.4.11. Stability testing ....................................................................................................... 106

xii

5.4.12 Powder X-ray diffraction ......................................................................................... 106
5.5. RESULTS AND DISCUSSION ...................................................................................... 107
5.5.1 Thermal Analysis ....................................................................................................... 107
5.5.2. DSC Miscibility studies ............................................................................................ 108
5.5.3. Solubility parameters calculation .............................................................................. 109
5.5.4. Hot Melt Casting ....................................................................................................... 110
5.5.5. Effect of Particle size on Content and release profiles – C7 films ........................... 113
5.5.6. Near Infrared Chemical Imaging .............................................................................. 115
5.5.7. In vitro release studies – HME films ........................................................................ 117
5.5.8. Statistical analysis of release profiles ....................................................................... 124
5.5.9. Stability studies ......................................................................................................... 126
5.6. CONCLUSION ................................................................................................................ 129
CHAPTER VI
Clotrimazole-Cyclodextrin complex for treatment of vaginal candidiasis ................................. 130
6.1. ABSTRACT ..................................................................................................................... 130
6.2. Introduction ...................................................................................................................... 131
6.3. Materials .......................................................................................................................... 134
6.4. Methods............................................................................................................................ 134
6.4.1. HPLC method ........................................................................................................... 134
6.4.2. Phase Solubility Studies ............................................................................................ 135
xiii

6.4.3. Characterization of Complexes ..................................................................................... 135
6.4.3.1. Differential Scanning Colorimetry ........................................................................ 135
6.4.3.2. Fourier Transform Infrared Spectroscopy (FTIR) ................................................. 136
6.4.3.3. Nuclear Magnetic Resonance Spectroscopy (NMR) ............................................. 136
6.4.3.4. Powder X-ray Diffractions studies......................................................................... 136
6.4.3.5. Scanning Electron microscopy .............................................................................. 137
6.4.4.1. Preparation of Cyclodextrin Complexes .................................................................... 137
6.4.4.2. Formulation of Gel ................................................................................................. 137
6.4.4.3. In vitro Release studies .......................................................................................... 138
6.4.4.4. Antifungal Testing of the Gels ............................................................................... 139
6.5. RESULTS AND DISCUSSION ...................................................................................... 140
6.5.1. Phase Solubility ............................................................................................................ 140
6.5.1.1. Thermal studies ...................................................................................................... 142
6.5.1.2. Fourier Transform Infra-Red spectroscopic analysis (FTIR) ................................ 143
6.5.1.3. Nuclear Magnetic Resonance Spectroscopic analysis ........................................... 145
6.5.1.4. X-Ray diffraction studies ....................................................................................... 146
6.5.1.5. Scanning Electron Microscopy (SEM) .................................................................. 148
6.5.2. Dissolution Testing Release Profile .......................................................................... 150
6.5.3. Antifungal Testing .................................................................................................... 152
6.6. Conclusion ........................................................................................................................... 153
xiv

BIBLIOGRAPHY ....................................................................................................................... 154
VITA ....................................................................................................................................... 178

xv

LIST OF TABLES
Table: 1- 1. Carriers used to prepare hot-melt extruded dosage forms ......................................... 19
Table: 3- 1. Formulation Composition - Pellets............................................................................ 44
Table: 3- 2. Formulation Composition - Tablets .......................................................................... 46
Table: 3- 3. Effect of drug loading on in vitro release, f2 values .................................................. 67
Table: 3- 4. % In vitro release from tablets at 25mg strength in 30 min. ..................................... 71
Table: 5- 1. Formulation composition of films ........................................................................... 102
Table: 5-2. Solubility parameter values for CLPM and excipients ............................................ 109
Table: 5-3. Release models and coefficients............................................................................... 123
Table: 6- 1. Release coefficients obtained from various dissolution models ............................. 150

xvi

LIST OF FIGURES
Figure: 1-1. Component sections of a Single Screw Hot Melt Extruder ...................................... 11
Figure: 1- 2. Schematics of an Extruder Screw [adapted from Ref. [24]] .................................... 12
Figure: 1- 3. Types of Screw elements [adapted from Ref. [33]] ................................................. 13
Figure: 1- 4. Cyclodextrins structure and Inclusion complex formation. Ref.[99]....................... 26
Figure: 1- 5. Phase solubility plot of CD complexes .................................................................... 28
Figure: 3- 1. TGA spectra of KPR and Polymers ......................................................................... 50
Figure: 3- 2. (a-b) HSM images of H1 &H2 Formulations .......................................................... 51
Figure: 3- 3. Polymer drug miscibility studies- DSC thermograms first heating step .................. 53
Figure: 3- 4. Polymer drug miscibility studies- Onset and Peak Temperatures obtained from DSC
thermograms ................................................................................................................................. 53
Figure: 3- 5. Effect of processing conditions on Post Extrusion drug content ............................. 56
Figure: 3- 6. (a-b) Moisture uptake study – H1 to H4 formulations ............................................. 58
Figure: 3- 7. PLM images of extruded pellets .............................................................................. 59
Figure: 3- 8. a-e SEM images of pellets manufactured using Klucel™ ELF polymer ................. 61
Figure: 3- 9. In Vitro release of EF and ELF pellets .................................................................... 62
Figure: 3- 10. In Vitro release of KPR pellets at different drug loading ...................................... 66
Figure: 3- 11. I-IV) SEM images of pellets manufacture using Klucel™ ELF polymer – Post
exposure to dissolution media ....................................................................................................... 70
Figure: 3- 12. In Vitro Release profiles of tablets at 25mg. strength ............................................ 72
xvii

Figure: 3- 13. In Vitro Release comparison to a marketed capsule formulation .......................... 73
Figure: 3- 14. mDSC thermograms of Pellets - 6 months stability............................................... 75
Figure: 3- 15. DSC thermograms Pellets -6 month’s stability ...................................................... 76
Figure: 3- 16. XRD images of H4-25T tablets: 6 months storage time point ............................... 77
Figure: 4- 1. Texture Analyzer plot .............................................................................................. 84
Figure: 4- 2. Excipient compatibility studies - DSC thermograms, Post storage of 14 days........ 86
Figure: 4- 3. Compressibility profiles of extruded matrices ......................................................... 87
Figure: 4- 4. Compactibility profiles of extruded matrices........................................................... 89
Figure: 4- 5. Tabletability profiles of extruded matrices .............................................................. 90
Figure: 4- 6. Tablet Hardness evaluation – Extruded vs. Un-Extruded ........................................ 92
Figure: 4- 7. % Change in Diameter on compression ................................................................... 94
Figure: 4- 8. Work of failure at tablet failure................................................................................ 94
Figure: 5- 1 TGA Thermograms of CLPM, RSPO, HPC, PEO and C7 formulations Physical
mixture ........................................................................................................................................ 107
Figure: 5- 2. DSC thermograms of Physical mixture of CLPM at 10% drug load ..................... 108
Figure: 5- 3. In vitro release comparison of HMC patches C1, C2, C3 (n=3) ............................ 111
Figure: 5- 4 In vitro release comparison of HMC films – a. Effect of RSPO concentration ...... 111
Figure: 5- 5. In vitro release comparison of HMC and HME films (n=3) .................................. 112
Figure: 5- 6. In vitro release profiles of C7 HME Formulation utilizing un-sieved polymers ... 114
Figure: 5- 7. Particle Size analysis of polymers used to manufacture C7 formulation .............. 114
Figure: 5- 8. NICI images of films with distributions based on a)CLPM, b) HPC, c)RSPO ..... 116
Figure: 5- 9. In vitro release profiles of HME films – Effect of RSPO concentration (n=3) ..... 118
Figure: 5- 10. Time take for 50% and 80% Release – Effect of RSPO polymer........................ 119

xviii

Figure: 5- 11. In vitro release profiles of HME films – Effect of HPC ...................................... 120
Figure: 5- 12. Time take for 50% and 80% Release – Effect of HPC polymer .......................... 121
Figure: 5-13. In vitro release comparison of HME films manufacutred using HPC+RSPO
polymers ...................................................................................................................................... 122
Figure: 5- 14. Response surface plot showing effect of concentration of HPC and RSPO on T50%
release ......................................................................................................................................... 125
Figure: 5- 15. XRD Spectra of C7 films and excipients stored at different storage conditions . 126
Figure: 5- 16. In vitro release profiles of C7 formulation post storage ...................................... 128
Figure: 6- 1. Structure of Clotrimazole (CT) .............................................................................. 132
Figure: 6- 2. Phase Solubility curve of CT-HPCD in water ....................................................... 141
Figure: 6- 3. DSC Thermograms of Complex, HPCD, Physical mixture, Clotrimazole ............ 142
Figure: 6- 4. FTIR spectra of puree HPCD, Drug, Physical mixture and Complex ................... 144
Figure: 6- 5. Continuous variance plot of Complexed to un-complexed CT.............................. 145
Figure: 6- 6. PXRD images of pure drug, HPBCD, Physical Mixture, Freeze dried and Kneaded
complex ....................................................................................................................................... 147
Figure: 6- 7. SEM images of HPCD, CT and Complex.............................................................. 149
Figure: 6- 8. In vitro release studies of Gels from Complexed CT and Pure drug ..................... 151
Figure: 6- 9. Antifungal activity of CT in pure and complexed form......................................... 152

xix

CHAPTER I

INTRODUCTION
High throughput screening techniques and combinatorial chemistry employed in the
pharmaceutical industry has resulted in discovery of drug molecules with high potency and
improved biological activity [1]. However, utilization of solvents such as DMSO and PEG for
biological screening has resulted in compounds with decreased solubility entering development
pipelines. Most of these compounds tend to be crystalline solids with high molecular weights,
lipophillic character and have often been referred to as ‘brick dust’ compounds. Oral delivery of
such compounds thus, becomes challenging and has led to emphasis in research on various
solubilization techniques.
Modified Noyes Whitney equation sums up the factors that influence dissolution rate of a
drug in the dissolution media [2].

Equation 1-1.

Where, dC/dt is the rate of dissolution, A is the surface area available for dissolution, D is
the diffusion coefficient, Cs is the solubility of the compound in the dissolution media, C is the
concentration of the drug in the media at time t, and h refers to the thickness of the diffusion
layer of the dissolving drug. Dissolution is an extrinsic property and can be altered, - by
increasing the surface area, increase wettability by the addition of hydrophilic polymers,
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increasing diffusivity and/or by decreasing the thickness of diffusion layer. Solid dispersions,
Complexation, Co-crystals, Lipid delivery systems primarily employ these principles in
enhancing dissolution and bioavailability of poorly soluble compounds [3]. Solubility of a drug
is an intrinsic property and can only be altered chemically via formation of salts or prodrugs.
Most of the poorly soluble drugs are crystalline solids with well-defined molecular
structures and are thermodynamically stable. Conversion of a crystalline compound to its
amorphous form has been found to be useful in enhancing solubility of such compounds [4].
Amorphous forms have a higher Gibbs free energy and lack long range molecular order, unlike
crystalline compounds, which results in an increase in dissolution rate [5]. However, high-energy
forms tend to revert to their more stable, low energy crystalline forms during processing or on
storage. Successful utilization of this technology thus, requires stabilization and prevention of
form conversion.
Solid dispersions and solid solutions that employ a carrier matrix, have been found to be
immensely useful in enhancing solubility by increasing surface area of the drug and
simultaneously stabilizing the amorphous form. Another technique that has attained importance
in the last ten years include co-crystals [5] and forming inclusion complexes utilizing CD’s [6].
Most of these CD’s are labeled as safe excipients and have been utilized in as many as 40 oral
and parental formulations. Lipid based Self-emulsifying drug delivery systems (SEDDS) are
isotropic mixtures that readily form an emulsion in the lumen and result in increased solubility.
They also aid in absorption due to enhanced lymphatic uptake of poorly soluble drugs [7-9].
Most of the solubilization techniques either involve utilization of organic solvents or are multiple
step batch processes that significantly increase processing time. Techniques such as
complexation and co-crystals also suffer from problems associated with scale up.
2

1.1. Solid Dispersions and Solid Solutions
Solid dispersions (SD) have been defined by Chiou and Riegelman as “ the dispersion of one
or more ingredients in an inert carrier or matrix, where the active ingredients could exist in
finely crystalline, solubilized or amorphous state” [10]. Carriers are typically long chain
polymers with better aqueous solubility than the drug molecule and selected based upon their
ability to disperse or solubilize the drug. Depending upon the extent of solubilization of drug in
the polymer, SD’s can be classified as eutectics or solid solutions [11]. Eutectic SD’s refer to
matrices wherein the drug is distributed in a microcrystalline state in a polymer matrix. Solid
solutions and solid dispersions refer to a molecular distribution of component systems where
one system cannot be discerned from the other. A lack of crystalline character of the drug in the
matrix is often referred to as a solid solution.
Techniques such as Differential scanning calorimetry (DSC), X-ray diffraction (XRD),
Polarized light microscope (PLM) and Infrared spectroscopy are commonly utilized to identify
the type of solid dispersion. DSC and XRD studies also enable one to establish miscibility as
well as solubility of the drug in the polymer matrix. Analytical techniques currently available
fail to detect low levels of crystallinity that differentiate solid dispersions from solid solutions
and hence the terms are used interchangeably. Solid solutions, in which the polymer and drug
exist in an amorphous form, are the most commonly employed to enhance solubility of poorly
soluble drugs. Long chain polymers such as Hydroxypropyl cellulose (HPC), Polyvinyl
pyrrolidone (PVP) or Polyethylene glycols (PEG) are most commonly utilized as they exist in
an amorphous form and are also hydrophilic in nature. Also, these polymers can be synthesized
with wide range of molecular weights and can be utilized to achieve tailored release.
Amorphous form of the drug in SD’s tend to recrystallize on storage and these polymers can
3

address such issues by preventing such transformations. Polymers with high glass transitions
temperatures prevent recrystallization by stearic hindrance whereas those with functional groups
might form hydrogen bonds preventing recrystallization.
1.1.1. Advantages and Disadvantages Solid dispersions
Solid dispersion is a proven, viable technology that has been used extensively for
solubility enhancement of poorly soluble drug due to its inherent advantages [11]. Increase in
solubility from SD’s has been attributed to increased surface area and wettability due to
hydrophilic polymers which results in a decrease in thickness of the diffusion layer. The
processing steps involved in formation of SD’s result in physico-chemical transformations that
favor increased solubility. Conversion to a high energy amorphous form, being one of them, can
also impart enhancement in solubility and bioavailability [12, 13]. In certain cases conversion of
amorphous drug to microcrystals in SD’s was found to have better dissolution than the pure drug
[14].
Solid dispersions are manufactured using hydrophilic carriers which, owing to their high
solubility, might leach out, resulting in precipitation of the drug. Also, most of the SD’s employ
amorphous form of drugs which tend to revert back to more stable, crystalline forms, thus
affecting release profiles. Hydrophilic polymers tend to absorb moisture on storage which allows
for an increase in free volume, and subsequently, crystallization. Also, it is in the best interest of
oral formulation development, that there exists high solubility of drug in the polymer matrix, as
it results in smaller dosage forms. Exceeding this solubility limit may result in phase separation
or crystallization. In Ritonavir SD’s, it was observed that an increase in drug loading resulted in
a corresponding faster in vitro release, but did not reflect in in vivo testing [15]. This difference
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was attributed to phase separation occurring at higher drug loading. Rapid release occurring due
to SD’s of atorvastatin resulted in a super saturated solution from which the drug precipitated
out, decreasing the bioavailability [16].
1.1.2. Manufacturing Methods
One of the hurdles towards development of solid dispersion or a solid solution, as noted
by Serajuddin include – method of preparation, reproducibility, process scale up leading to
manufacturing, and physico-chemical stability on storage [12]. Thus, a suitable carrier and a
process that can manufacture a suitable matrix, aiding stability of SD’s, becomes a crucial step
towards successful utilization of this technique. Many methods have been developed to
manufacture solid dispersions notably - solvent evaporation [17], fusion method [18, 19],
complexation, spray drying [20] and hot melt extrusion [21, 22].
Solvent evaporation is the most common and simplest of the techniques used. Drug and
polymer are solubilized in a common solvent, usually an organic solvent, and dried via tray,
Rotovap or Vacuum drying, to form SD’s. Though, it is a feasible and simple technique for
initial screening, it suffers from scale up issues. Spray drying process utilizes a similar principle
and has been extensively used to form SD’s on a commercial scale. Spray drying has been in use
in pharmaceutical industry for the manufacture of inhalation formulations and has already
addressed many of the issues with scale up. This has accelerated it as an important technique for
the manufacture of SD’s. Formulations obtained are spherical, free flowing and can be easily
processed further. However, it suffers from the drawback that it is a solvent based batch process
that requires both drug and polymers be soluble in a common solvent.

5

Research in Solubility enhancement has gained prominence in last ten years due to an
increase in highly crystalline, poorly soluble drug compounds. Techniques such as HME and
spray drying have been a ‘go to’ technology to form amorphous solid dispersions of these low
soluble agents. With the advent of new polymers, problems such as phase separation,
crystallization, precipitation and agglomeration have been duly addressed thus propelling
efficient utilization of these techniques.
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1.2. Hot Melt Extrusion
Hot melt extrusion (HME) is a versatile processing technology that can be used for
solubility enhancement, granulation and as a physico-chemical stability imparting system. Being
a non-solvent process, HME has significant utility in manufacture of solid dispersions and solid
solutions. The process involves melting or softening of drug/s and excipients in a heated barrel
which are then pushed through a die, to yield extrudates of various shapes and sizes [23]. The
intense mixing and shearing distributes the drug uniformly in a polymer matrix and depending
upon the drug and polymer interactions, aid formation of a solid solution or a solid dispersion
[24]. The heating process and the polymers further aid the conversion of a crystalline drug to an
amorphous form, thus contributing towards increased surface area. The extrudates, as per
requirement, can be further processed into pellets as multi-particulate systems, films or into
tablets by milling and addition of tabletting excipients [25].
Thermoplastic polymers that can withstand high temperatures and shear are exclusively
used in HME to form solid dispersions or solid solutions. Processing aids can be added to further
decrease the viscosity of the melted matrix [26], as pore formers or to impart physico-mechanical
properties to the extruded matrix. Unlike other processes commonly employed in pharmaceutical
industry, HME is a continuous process and can be scaled up easily. Being a process that is
performed at high temperatures, the polymers and the drug have to meet the requirement of being
thermoplastic, thermostable and withstand the shear exerted by the screws.
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1.2.1. Types of Extrusion Process
Extrusion processing involves two different types of extrusion, referred to as dry
extrusion and the other being wet extrusion. Wet extrusion, as the name suggests involves the
use of solvents such as water or alcohols that are utilized to activate a binder, creating a wet
mass. The mass is then extruded through a sieve to form spaghetti like strands that are
spheronized to form pellets. Wet extrusion results in product that are uniform in nature and have
a better finish due to ripening action of the excipients [27]. Also, this method is more suitable for
drugs and excipients that are heat sensitive as there is less buildup of localized heat. Dry
extrusion is a non-solvent process involving thermoplastic agents that melt at high temperatures
to form homogenous matrices inside a hot melt extruder.
1.2.2. Schematics and Components of a Hot Melt Extruder
Hot melt extrusion has been in use in plastics industry for a long period of time. Hence,
most of the instrumentation and post processing equipment employ similar designs that have
been adapted to accommodate pharmaceutical requirements. Essentially, a Hot melt extruder can
be divided into sections such as feeding, heating, conveying, metering and die sections.
Based on the conveying mechanism used, there are essentially two types of hot melt
extruders. A ram extruder employs a piston as a conveying element. The material is fed into a
heated barrel and allowed to melt before being pushed out by a positively displacing piston, that
forces the material through a die plate [28]. Drawbacks with such an extruder include nonuniform heat distribution, improper melting and a non-homogenous distribution of the
components due to lack of mixing elements.
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1.2.3. Screw based Extruder
Screw based extruders are most commonly utilized in pharmaceutical industry as it aids
in more efficient mixing. As the name suggests these extruders utilize a screw that spans the
entire length of the barrel, conveying material from feeding section to the discharge plate.
Screws allows for feeding, conveying, blending and metering operations and also in pushing the
material out through a die. Screw extruders allow for uniform melting and mixing of components
and hence result in a more homogenously distributed extrudate. These extruders are primarily
two types, single screw and twin screw extruders. Single screw extruders, as the name suggests,
have a single screw element that rotates and mixes the components in a heated barrel. These
extruders are able to handle immense pressure build up that can occur with viscous material, at
the same time maintaining consistent pressure. Screw with diameter less than 18mm, as they
taper towards the discharge end, tend to lose their discharge capacity. Hence, these extruders are
designed with a motor on the discharge end to increase discharge capacity [29]. The components
of a screw based extruder include – drive motor, barrel, and screw elements.
1.2.3.1. Driving motor
Driving motor is the heart of the extrusion system providing the necessary torque
required to rotate the screws and convey the material. Process control parameters such as motor
torque, amperes, and rotations per minute (rpm) are continuously monitored to evaluate success
and feasibility of HME process. If needed, suitable processing aids can be added to improve the
extrusion process [30, 31]. Residence time is the amount of time material is inside a barrel and is
directly related to motor speed. Thermally sensitive compounds undergo degradation on
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continued exposure to heat and hence a lower residence time significantly decreases this
possibility.
1.2.3.2. Barrel
Barrel of an extruder is designed to conduct heat and, be able to withstand the pressure
and mechanical stress generated due to the rotating screws. Additionally, it should be easily
accessible to be cleaned at the end of an extrusion process. Depending upon the manufacturer,
two types of barrels are primarily used. A monoblock design constitutes a single block of steel
with access for feeders, screw elements and temperature controlling units (Ex. Leistritz ®
Nano18). Second type of barrel unit involves a clam-shell design that allows for separation of
upper and lower sections. The sections are held in place by a series of screws with heating units
placed in the bottom section. Extruders manufactured by Thermo Scientific®, Brabender® are
based on this design. Clam shell design allows for ease of access in cleaning the screws and the
barrel but also suffers from a possibility of molten material leaking out, if not tightened very
well. Monoblock design circumvents this disadvantage but suffers from the fact that screws and
barrels cannot be easily taken out for cleaning purposes when viscous polymer is used.
Temperature of the barrel is controlled by heating elements and thermocouples. Modular design
based barrels consists of multiple zones which can be accurately maintained at different
temperatures as required. This also allows for flexibility to use different temperature profiles
such as maintaining the zone closes to the feeding at lower temperature and the die at a higher
temperature to aid extrusion by decreasing viscosity. Some extruders also have a built in cooling
mechanism near the feeding section to prevent sticking of material. The barrel of an extruder can
be divided into sections – feeding zone, conveying zone, compression zone, metering zone and
discharge zone as shown in the figure 1-1.
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Figure: 1-1. Component sections of a Single Screw Hot Melt Extruder

1.2.3.3. Screw Elements
Screw design plays an important role in extruder design and it can be altered to address
specific needs of the formulation. Figure 1-2, represents a cross-section of a screw in a barrel.
The channel depth is the distance between the screw and the barrel. This is widest at the feeding
zone to allow material to be added and is narrowest at the compression zone. The compression
zone of an extruder has a decreased channel depth allowing for the entrapped air to be squeezed
out as well as to allow for thorough mixing [32]. Channel width is the space between each
individual thread on a screw. These are spaced out in the feeding section to allow for more
material to fall and decreases in the compression zone. Metering zone has the screw elements
placed with uniform channel width to allow for uniform output.
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Figure: 1- 2. Schematics of an Extruder Screw [adapted from Ref. [24]]

Current HME screws employ a modular design that allows for elements that can be
interchanged as per need. Screw elements thus, can be altered to achieve increased shearing or
conveying, as required by intended application. Figure 1-3 refers to different types of screw
configurations that can be utilized [33]. Conveying elements are the least aggressive and as the
name suggests, are used to convey the material forward. They are usually arranged next to
feeding zones and might also have a wider channel width. Dispersive elements allow for
maximum shear and aggressive mixing, and depend upon conveying elements to move the
material forward. Dhumal et al observed that formation of co-crystals was maximum when more
dispersive elements were added to screw configuration as it allowed for intense shearing [33].
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Figure: 1- 3. Types of Screw elements [adapted from Ref. [33]]

1.2.3.4. Twin screw extruders (TSE)
TSE’s employ two screw elements that either rotate in opposite direction (counter
rotating) or in same direction (co-rotating). These extruders allow for easier feeding, better
mixing and dispersion of component systems, de volatilization, reduced heat generation and a
shorter residence time. TSE’s are the most commonly utilized extruders in the pharmaceutical
industry and the choice to use a counter or co-rotating extruders depends upon the intended
application. Counter rotating TSE’s allow for intense mixing, high shear and in dispersing
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materials more uniformly. The drawbacks of using such a system include high air entrapment
and generation of excessive heat and stress, which might result in product degradation. Also,
counter rotating screws experience excessive wear and tear due to outward push of the material
and cannot be operated at high speeds. Co-rotating extruders allow for high speeds and
significantly bring down the wear and tear on the motor and screws. These screws are typically
intermeshing and hence are self-cleaning, allowing for a reduction in localized heat generation.
1.2.3.5. Discharge and Post Processing Equipment
Die is the final component of an extrusion system and is used to shape the extrudate
material. It consists of a perforated or shaped opening in a steel block and is attached to the distal
end of an extruder. Die also holds ports for pressure transducers, thermocouples, and probes that
aid in analytical analysis of the extrusion process and can be used as a process analytical tool
[34, 35]. Depending upon the intended final dosage form, different die are utilized to shape the
extrudate material. A flex lip die allows for manufacture of films for transmucosal, transdermal
or transungal applications [36, 37]. A chill roll is utilized to cool the film and to maintain
uniform thickness by passing it in between spaced rolls. Cylindrical die allows for extrudate rods
that can be further processed into pellets, mini matrices or, milled for tabletting applications.
Temperature control of die is of crucial importance as it aids in managing the pressure
and material characteristics post extrusion. Highly viscous material undergoes compression when
pushed through the die resulting in a decrease in porosity. Viscoelastic polymers such as HPC
and PEO undergo die swelling on exiting the die. Increasing the temperatures, hence, reduce the
viscosity and aids extrusion of such polymers. Post processing equipment is essentially utilized
to cool the extrudates or in certain cases to further shape the extrudates, as in injection molding
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applications. Die with a built in rotating knife has been utilized to cut extrudates and form
spheres through a spheronization process. In certain special applications such as granulation,
extruders are operated without a die to prevent compression of the material. Vasanthavada et al
evaluated applications of HME as a granulation technique by operating the extruder without a die
plate to form granules and compressed them into tablets [38].
1.2.4. Carriers and Processing Aids
HME process involves intimate mixing of carrier components and active ingredients to
form a homogenous system that stays stable during the intended period of storage. Carriers not
only aid in formation of a solid dispersion of the amorphous drug, but, also aid in maintaining
the high energy state. These carrier molecules have to meet the requirement of being thermally
stable and withstand the shear being exerted by the screws without degrading. Thermoplastic
polymers that can withstand high temperatures are exclusively utilized in HME to form solid
dispersions or solid solutions. Processing aids can further be added to decrease viscosity of the
melted matrix, increase stability, as pore formers or to impart physico-mechanical properties to
the extruded matrix.
Being a hot process, thermo stability and plasticity of all components is critical and
various analytical techniques are utilized the asses the same. Initial screening studies typically
involve thermal characterization techniques such as Thermo-gravimetric analysis (TGA), and
Differential scanning colorimetry (DSC) [39-44] and in some cases, may also involve Gel
chromatography studies [45, 46] for chemical stability assessment of polymers.
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1.2.4.1. Carrier materials
Carrier materials and processing aids are the most important components of an extrusion
system. Depending upon the intended application of the final dosage form, many polymeric and
non-polymeric material have been evaluated for HME applications. Most of the polymers
utilized are high molecular weight compounds and are either semi crystalline or crystalline in
nature.
Polyethylene oxide (PEO) polymers are free flowing, semi crystalline polymers,
synthesized by heterogeneous catalytic polymerization of ethylene oxide monomers. These
polymers have a melting range between 57-73°C and are available in a wide range of molecular
weights ranging from 100 to 800 Kilo Daltons. PEO polymers are water soluble in all ratios, with
higher molecular weight polymers requiring longer time to dissolve. Due to their thermoplastic
behavior, PEO polymers have been utilized for various applications in HME such as immediate
to controlled release, and due to plastic nature, as plasticizers [45]. However, these polymers
undergo oxidative degradation at high temperatures and hence require antioxidants.
Cellulose based polymers are obtained by alkylation of naturally occurring celluloses and
have a wide applicability in pharmaceutical industry. Polymers with a wide variety of viscosities
and solubilities can be synthesized by altering the extent of substitution. Cellulose ethers such as
Hydroxyethyl cellulose (HEC) and Hydroxypropyl cellulose (HPC) have been utilized in HME
owing to their stability and release characteristics [36, 37, 47, 48]. HPC is a nonionic, water
soluble, thermoplastic cellulosic ether and has been extensively utilized due to its organic, as
well as aqueous solubility, and surface activity [49]. HPC polymers have a fixed molar
substitution and hence molecular weight is altered by controlling degree of polymerization.
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These polymers undergo dissolution by swelling and erosion mechanism which is molecular
weight dependent [50]. Klucel™ HPC EF and ELF hydroxypropylcellulose are nonionic,
thermoplastic, and lower molecular weight polymers with a molecular weight of approximately
80,000 and 60,000 Daltons, respectively. HPC polymers have been used previously to control
drug release from hot melt extruded films [51, 52] and as a granulation binders [53].
Hydroxypropylmethyl cellulose is a partly o-methylated and o-(2-hydroxypropylated)
non-ionic cellulose ether typically utilized as a release modifying agents. HPMC has high glass
transition temperature and hence require a plasticizer for HME applications. Repka et al
characterized blends of Hydroxypropyl methyl cellulose plasticized using Hydroxypropyl
cellulose films manufactured via HME [52]. Depending upon acetyl and succinoyl substitution
on HPMC, HPMC-AS polymers with varied pH sensitivity have been synthesized. These
polymers do not dissolve in gastric fluid but swell up in gastric media and exhibit diffusion
controlled release of the drug [54, 55]. Ethyl cellulose polymers are water insoluble,
thermoplastic, compressible polymers and have been evaluated as control release agents in HME
[30, 56].
Polymethacrylate polymers are synthesized by varying ratios of dimethylaminoethyl
methacrylate, methacrylic acid and methacrylic acid esters. These polymers have been utilized in
HME for wide variety of applications ranging from controlled release [43], immediate release
[57, 58], enteric coating [59], as well as for taste masking [60] applications. Polyvinyl
pyrrolidone (PVP) polymers are another class of synthetic polymers consisting of linear chains
of 1-vinyl-2-pyrolidone,that have been utilized as carriers in HME. Similar to HPC, PVP
polymers are manufactured by varying the degree of polymerization resulting in compounds with
different molecular weights. PVP polymers are highly water soluble and have been known to
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maintain physical and chemical state of the drug [61]. Kollidon VA-64, a copolymer of
vinylactetate and PVP, is an excellent solubulizer and has been utilized to increase
bioavailability of poorly soluble drugs [62]. Most of the solid dispersions utilize an amorphous
form of the drug, which being a high energy form, tends to recrystallize back. VA-64 in addition
to forming solid dispersions, has been found to maintain the amorphous form, preventing its
recrystallization [63, 64].
In addition, other non-polymeric materials have been explored in HME as a carrier
material, fillers or to modify release profiles. Bialleck et al utilized starch to manufacture pellets
with decreased porosity, a narrower particle size distribution, improved dissolution and
compared them to pellets manufactured using conventional extrusion-spheronization processes
[65]. Liu et al utilized waxes as thermal binders which also aided in retarding the release in
extrudates [66]. They also evaluated excipients such as microcrystalline cellulose and lactose as
fillers. Sugars such as Isomalt [67], Erythritol [68] and Mannitol [69] have been explored in
HME to form solid dispersions and effect solubility. Isomalt when coextruded with paracetamol
was found to enhance tabletting properties due to conversion to an amorphous form [70].
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Table: 1- 1. Carriers used to prepare hot-melt extruded dosage forms
Chemical Name

Trade Name

Tg (C)

Tm (C)

Ammonio methacrylate copolymer

Eudragit® RS/RL

64

--

Poly(dimethylaminoethylmethacrylate-

Eudragit® E

50

--

Eudragit® S/L

160

--

Cellulose Acetate Phthalate

--

165

192

Poly(vinyl pyrrolidone)

Kollidon®

90-156

--

Poly(vinyl acetate)

Sentry® plus

35-40

--

Hydroxypropyl Methylcellulose

--

137

150

Polyvinyl pyrrolidone-co-vinyl acetate

Kollidon® VA64

101

--

Polyvinyl caprolactam-polyvinyl acetate-

Soluplus®

70

--

Methocel®,

160-210

--

~ 120

--

co-methacrylic esters)
Poly(methacrylic acid-co-methyl
methacrylate) 1:2

Phthalate

polyethylene glycol graft copolymer
Hydroxypropyl Methylcellulose (HPMC)

Benecel®
HPMC Acetate Succinate

Aqoat-AS®

Ethyl cellulose

Ethocel®

130-133oC

Aqualon® EC
Hydroxypropyl Cellulose

Klucel®

Softens at 130oC

Polyethylene Glycol

Carbowax®

-17oC

Polyethylene Oxide

PolyyOx® WSR

-57 to -50oC

62-67oC

Polymethacrylates

Eudragit ® RSPM

52oC , 40oC

--

37-63oC

Eudragit ® E
81-86oC

Carnuba Wax

---

Glyceryl palmitostearate

Precirol ATO 5®
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----

52 -55 oC

1.2.4.2. Processing Aids
Extrusion is a mechanical process that involves mixing and blending operations brought
about by rotating screw or screws. The torque exerted by the screws is dependent upon the
viscosity of the melt and plasticizers help in reducing the torque on the motor. They also play an
important role in improving physico-mechanical properties of the extruded dosage forms,
imparting flexibility in certain cases. A decreased viscosity also aids in better processing
conditions such as lower barrel temperatures, higher screw speeds and a decreased residence
time which, overall helps in reducing energy consumption and increased efficiency of the
extrusion process. For thermally sensitive compounds, a decrease in residence time can also
mean improved stability due to less exposure to heat. Most of the HME polymers utilized are
semicrystalline polymers with high glass transition (Tg) temperatures [59]. Plasticizers are able
to decrease Tg and increase the polymeric free volume, thereby decreasing the required
processing conditions [71]. Shorter chain length polymers orient themselves between longer
polymer chains allowing for increased polymer spacing and weakened polymeric intermolecular
interactions. These compounds also allow polymeric materials to change configuration, thus
allowing them to slide over each other upon exertion of stress. Lower molecular weight grades of
polymers such as, polyethylene glycols [26, 72] and polyethylene oxides have been extensively
used as plasticizers. Low melting, small molecule drugs, when extruded with viscous polymers
have been observed to act as a plasticizers and aided the extrusion process [26, 73, 74].
Triethyl citrate (TEC) was utilized by Bruce et al to plasticize Eudragit® S prior to
extrusion, utilizing a granulation method, as TEC is a liquid [59]. It was found that addition of
TEC decreased the Tg due to reduced intermolecular interactions among the polymer chains.
TEC has been utilized as a plasticizer with other acrylic polymers and to improve mechanical
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properties [43, 75, 76]. Absorbed moisture was found to have a plasticization effect on extruded
HPC films and thereby contributed towards increased ductility [37]. Repka et al reported
advantages of Vitamin E TPGS as a plasticizer [72]. Andrews et al reported that extruded
material, as they are being pushed through the die undergo a loss in porosity [41]. Plasticizers
may affect the product on storage due to volatilization over a period of time, effecting release
and mechanical integrity. Repka et al observed in extruded films of Hydrocortisone (HC), in
which HC acted as a plasticizer, an increase in brittleness corresponded to a decrease in HC
content on storage [26]. Transient or temporary plasticizers, such as carbon dioxide or water
have been explored to counter this disadvantage. Verreck et al reported that pressurized or
supercritical Carbon dioxide was found to decrease the Tg of semicrystalline polymers as well
act as a foaming agent, thereby increasing porosity of the extruded material [77-80]. Plasticizers
also play a very critical role in development of films for transmucosal [81] and transdermal
applications as they aid in maintaining required film flexibility. Cilurzo observed that films with
rapid release could be manufactured utilizing Maltodextrins in combination with film forming
polymers [82]. They evaluated plasticizers based on flexibility, tensile strength, and adhesiveness
of films and their effect on release. Citric acid has been found to be a good plasticizer as well as
a release modifying agent by altering the micro environmental pH [42].
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1.2.5. Pharmaceutical Applications of Hot Melt Extrusion
HME processing has gained prominence in recent times due to its applicability as a
solubility enhancing technique for poorly soluble drugs [64]. With appropriate selection of
polymers, stable solid dispersions of poorly soluble drugs can be manufactured in a one-step,
continuous process. Formulations comprising, tablets, capsules, films or mini-matrices can be
manufactured with slight modification to extruder and addition of post processing equipment. He
et al evaluated the advantages of Eudragit E100 and PVP-VA copolymer in enhancing solubility,
and thereby, bioavailability of Fenofibrate [14]. HME was able to form microcrystals of the drug
in a hydrophilic matrix, which resulted in faster dissolution due to increased surface area.
Amorphous Nimodipine solid dispersions manufactured utilizing Kollidon polymers exhibited
enhanced solubility and stability on storage [39]. HME has also been utilized to form complexes
of β-cyclodextrin and a poorly soluble drug to enhance its solubility. The technique was found to
be faster, and an efficient method for the manufacture of complexes [83]. SD’s commonly
employ amorphous form of the drug to enhance solubility, however they suffer from, form
reversion on storage. Thommes et al utilized HME to address these issues by forming nano
crystalline SD’s of a poorly soluble drug using a crystalline excipient, which exhibited a faster
release and also remained stable [84].
Most of the polymers currently in use in pharmaceutical industry for modified release
applications can be utilized in HME to achieve targeted release profiles. HPC polymers marketed
under the name Klucel™, constitute polymers with a wide variety of molecular weights and have
been used extensively to modify release of soluble drugs [51, 81]. Hot melt extrusion process
allows for a wide selection of polymers that can be used to tailor profiles from immediate to
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controlled release [44, 85, 86] and in some cases, can be utilized for prolonged release
applications.
Special Applications
Extruded films, by the use of appropriate post-processing equipment, have been used to
shape formulations for transungal [48], transdermal [87-89], transmucosal, and other
biodegradable [90] applications. With the appropriate use of polymer- drug combination and post
processing equipment, HME can be utilized to manufacture films and implants, with desired
release and shape. HME manufactured injection molded implants exhibit uniform mixing and
distribution of components and aid in achieving desired release profile. Johnson et al were able
to manufacture dual drug segmented implants utilizing HME which was otherwise, not feasible
through conventional techniques [91]. Cheng et al utilized HME to manufacture implants for
prolonged release of Praziquantel, an anthelminthic drug, from Polycaprolactone matrices [92].
Other special applications include, formation of co-crystals, floating tablets for gastro
retentive delivery [93] and taste masking of bitter agents. Manufacture of Co-crystals is a tedious
process that involves either solvent based methods or intense mixing operations. Dhumal et al
were able to utilize a twin screw extruder to manufacture co-crystals of Ibuprofen and
Nicotanimide. Screw design with more aggressive mixing elements, rotating at low speeds
allowed for a maximum yield of co-crystals [33]. HME has also been utilized to form solid
dispersions of bitter drugs using appropriate polymers to mask their taste [94]. With the advent
of new polymers and plasticizers, processing temperatures have dropped significantly allowing
for extrusion of heat sensitive material and also bioactives such as lysozyme [95].
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1.3. Cyclodextrins
Cyclodextrins are cyclic oligosaccharides consisting of six α-Cyclodextrin, seven βcyclodextrin, eight ɣ- cyclodextrin or more glucopyranose units linked by α-(1,4) bonds. The
glucopyranose units, which exist in a chair like conformation, take the shape of a truncated cone
or torus in CD’s. Most of the derivatives currently in use, derive their origin from three types of
CD’s - α, β, and ɣ, and are considered to be parent CD’s. These cyclodextrins exhibit decreased
solubility due to stronger binding and crystalline characters. β-cyclodextrin molecules form
hydrogen bonds that prevent their solubilization in solutions.
Modification of CD’s utilizing cellulosic derivatives such as, Carboxymethyl cellulose
and Hydroxypropyl methyl cellulose has resulted in compounds with increased solubility. It was
observed that methylation of the hydroxyl groups on the outer ring resulted in a dramatic
increase in solubility of β CD’s. Several derivatives were later synthesized that include 2hydroxy propyl derivatives of β CD (HPbCD) and γ CD (HPgCD) and Sulfobutylether
derivatives of βCD (SBbCD). The solubility enhancement has also been attributed to the
conversion of crystalline CD’s to an amorphous mixture of isomeric derivatives [96]. The
reaction conditions employed, significantly affect the isomerization process and hence, CD
derivatives obtained from different manufacturers, or even from different batches differ slightly.
Complete substitution results in decreased solubility due to a drop in number of possible isomers.
Degree of substitution also affects the access of the CD cavity to the host molecule. However,
continued research in this area has resulted in many such derivatives being synthesized. Lack of
toxicological data on these derivatives limit their use to industrial applications as the current, and
time tested CD derivatives are able to satisfy the needs of pharmaceutical industry. Many of
these CD’s are categorized as ‘Generally Regarded As Safe’ (GRASS) by the FDA and have also
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been mentioned in the Pharmacopeias. Oral as well as parental formulations based on CD’s are
already marketed in the Europe and USA. Modified CD’s such as 2-Hydroxypropyl- βcyclodextrin (HPbCD), Sulfobutylether β-CD are approved by regulatory agencies and have
been used in parental formulations at high concentrations [97]. Japanese Pharmaceutical Codex
considers all the three α-, β - and γ- CD’s as safe and have been approved to be used as a food
additives.
1.3.1. Mechanism of Inclusion complex formation
CD’s are known to form inclusion complexes with wide variety of compounds ranging
from solid, liquids and gases by molecular complexation [98]. X-ray studies performed on CD’s
confirm presence of hydroxyl groups on outer edge, with apolar hydrogen’s and ether like
oxygen’s in the inner core. This distribution results in formation of a hydrophilic outer surface
and hydrophobic inner core. The presence of an inner cavity allows CD’s to form inclusion
complexes. Though height of CD cavity remains the same, diameter of the cavity is dependent
upon the number of glucose units. α-CD’s can thus accommodate small molecules whereas βCDs can accommodate aromatics and heterocyclic compounds [98].
Complexes are formed by replacement of enthalpy rich water molecules from the CD
cavity by a more hydrophobic guest molecule. There is apolar-apolar association that results in
reduction of ring strain and hence, is the driving force to form complexes. These associations are
non-covalent and in dynamic equilibrium with each other. Though complexes are formed
rapidly, equilibrium takes longer time to be established as the guest molecules are held by weak
Vander Waals forces. The lipophilic core of CD is made up of skeletal carbons and ethereal
oxygens and this lipophilic microenvironment provides a suitable cavity in which drug molecules
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can enter. The hydrophilic outer core lined with hydroxyl groups allow CD’s to form hydrogen
bonding with solvents and hence result in increased solubility. Binding strength depends upon
how close a fit is obtained between the guest and CD molecule.

Figure: 1- 4. Cyclodextrins structure and Inclusion complex formation. Ref.[98]
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1.3.2. Method of Manufacture of CD complexes
Various methods have been described in the literature for the manufacture of complexes.
Most of these methods utilize solvents in different proportions to either form a solution, slurry or
a paste and may involve heating and mixing steps to speed up the process. Water is the solvent of
choice as CD’s are most soluble and form complexes readily with poorly soluble drugs.
However, additional solvents might be utilized to compensate for decreased aqueous solubility of
poorly soluble drugs and such solutions then added to CD solution to form complexes. Addition
of water also helps formation of complexes for higher molecular weight compounds such as oils,
as it helps in preventing aggregation of oil molecules. Hot melt extrusion has also been utilized
as a means to form complexes of a poorly soluble drug with Sulfobutyl ether β-cyclodextrin and
β-cyclodextrin [83]. HME has an advantage of being a continuous process, however, the shear
generated may damage the structure of CDs. Commonly used complexation methods involve a
solvent removal step at the end of process and techniques such as spray drying, tray drying are
typically utilized [99]. Care must be taken during drying step as thermolabile drugs may degrade
due to excess heat built up. Processes like lyophilization or freeze drying are typically employed
for such compounds. Also these techniques convert the drug to an amorphous form thus further
enhancing solubility [100].

27

Complexation Efficiency
Formation of complexes is a dynamic process that involves association and dissociation
of formed complexes. Phase solubility analysis as described by Higuchi and Connors, is a widely
utilized technique to determine complexation constants and the complexation process, as such
[101]. Excess amount of drug is incorporated into vials containing CD solutions at successively
increasing concentrations and allowed to equilibrate over a period of time. Slope is then
calculated from the plot of molar concentration of drug dissolved to CD concentration. The
stability constant (K) can then be calculated utilizing the following equation.

Equation 1-2.
Where So stands for intrinsic solubility of the pure component
Depending on the type of curve formed, complexation is defined as either an A or a B
type. ‘A’ type plots suggests formation of a 1:1 inclusion complex and are further classified as
AL –linear increase in solubility as a function of CD concentration, AP –positively deviating
isotherm and AN –negatively deviating isotherm. B-type plots are suggestive of less
solubilization effect of CD and are often observed with β-CD’s [98].

Figure: 1- 5. Phase solubility plot of CD complexes
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Complexation Efficiency (CE)
Cyclodextrins form inclusion as well as non-inclusion complexes with ligands. Also,
CD’s tend to form aggregates, which becomes more prominent at high concentrations. Hence
experimentally determined K values might not be an accurate representation of complexation
phenomenon. Determination of So values for poorly soluble drugs (<0.01mg/mL) from the shake
flask method also can affect the K-values and result in an error. Complexation efficiency which
is calculated from the ratio of complex to free cyclodextrin concentration is a more exact
representation of the complexation process and can be calculated from the following equation
(Eqn.1-3)[102]. Owing to their large molecular weight, CDs’ add significant weight to
formulations and thus adding to final formulation weight. CE can be utilized to effectively
calculate formulation bulk phase, which is significant in oral dosage forms.

Equation 1-3.

Slope is calculated from the phase solubility plots mentioned earlier.
1.3.3 Applications of CD complexation
Cyclodextrins have a wide variety of applications due to their complex forming ability. In
pharmaceutical industry they are frequently employed to increase bioavailability of poorly
soluble drugs where dissolution is the rate limiting step. Cyclodextrins aid absorption of the drug
in the lumen, by maintaining it in a solubilized state. Complexation, being a dynamic process,
occurs simultaneously and involves association and dissociation of complexes. Precipitation can
occur if this equilibrium goes beyond the solubility of drug, and addition of inhibitors such as
PVP or HPC has been observed to be useful in such cases without affecting bioavailability [103].
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Sigurooardottir et al were able to utilize Maltosyl βCD (MbCD) and PVP to enhance transdermal
permeability of hydrocortisone [104]. They observed that at higher concentrations a drop in flux
was observed suggesting an upper limit to the concentration of MbCD that can be used for such
applications. CD’s have also been utilized to stabilize substances from hydrolytic, oxidative,
photolytic or enzymatic degradation. ɣ-CD’s have been used as a taste masking agent for bitter
drugs obtained from natural sources [105, 106]. In food and cosmetic industry, they have been
used as stabilizers and as taste masking agents and in pharmaceutical industry, they have been
used as rate controlling agents, solubilizers, decrease tissue irritation, and as odor masking agents
[107]. HPCD and RMβCD were able to enhance solubility and hydrolytic stability of Curcumin
[108]. Various derivatives of β-Cd’s were utilized to enhance stability of an anti-parasitic agent
to protect it from enzymatic as well as alkaline hydrolysis by forming complexes [109]. HPCD
has been utilized to increase soubility in parenteral formulations [110]. Various CD’s have been
investigated for their applicability in increasing the solubility of poorly water soluble drugs such
as Miconazole [111], Itraconazole [112], Sertaconazole [113], Clotrimazole, Bifonazole [114]
HPCD has been utilized to enhance release of a poorly soluble drug Carvediol from buccal
adhesive patches [115]. CD’s have allowed for enhancement in nasal as well as transdermal
absorption

of

certain
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drugs

[116].

CHAPTER II

Objectives and Model Drugs
2.1. Applicability and advantages of HME for solubility enhancement and as a processing
tool for capsule and tablet formulations using Klucel™ EF and ELF polymers
2.1.1. Objectives
The utility of HME has been explored as a processing method to increase solubility of a
poorly soluble model compound. HME was used to form amorphous solid dispersions of the
drug in a hydrophilic matrix comprising Klucel polymers EF and ELF. The following
objectives were accomplished in this work:
 Pre-formulation studies were performed to evaluate thermal stability and
miscibility of polymer and drug using TGA, DSC and Hot stage microscopy.
 Formulation design and optimization of HME processes were performed to
maximize yield for the manufacture of pellets
 Effect of drug loading and release modifying agents on in vitro release and release
mechanisms involved were studied
 In vitro release of direct compressed tablets manufactured from HME matrices
were evaluated and compared to a marketed formulation
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 The effect of storage conditions on formulations using Thermal, Chemical assay,
XRD and release profiles of formulations stored at different storage conditions
were studied
Secondary objectives of this study include investigation of tabletting behavior of blends
manufactured from HME matrices.
o Tabletting profiles and conventional tablet characterization tests were conducted
and evaluated

2.1.2. Model Drug - Ketoprofen

Figure: 2- 1. Chemical Structure of Ketoprofen

Ketoprofen (KPR) is a white or off-white, odorless, non-hygroscopic, fine powder. It is
freely soluble in ethanol, chloroform, acetone, ether and soluble in benzene and strong alkali, but
practically insoluble in water at 20° C. The solubility in ethanol, DMSO, dimethyl formamide is
at 20mg/ml. The solubility of Ketoprofen in PBS pH 7.2 is 0.5 mg/ml. has a low solubility in pH
1.2 buffer (0.06 μg/mL) and a high apparent permeability (> 1 × 10-6 cm/s). Ketoprofen is a
BCS class II drug, hence dissolution is the rate limiting step for oral bioavailability. It is
thermally stable, poorly soluble crystalline compound and was hence selected as a model drug
for this study.
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2.2. Formulation of controlled release film formulations utilizing polymers blends for water
soluble drug via hot melt extrusion
2.2.1. Objectives
The applicability of HME technology for the manufacture of controlled release film
formulation using a blend of Eudragit® RSPO, Klucel® EF and POLYOX™ N10 polymers were
investigated. The advantages of intense mixing of an extruder to manufacture homogenous films
from polymer blends that aid in tailored release profiles were evaluated. The research objectives
can be summarized as below:
 Thermal stability and miscibility evaluation of CLPM and other excipients
 To compare Hot melt cast as a fast screening technique prior to HME
 Optimization of HME process to extrude films with homogeneous drug and
polymer distribution.
 Characterization of films utilizing drug content analysis, in vitro release
studies and chemical imaging techniques.
 To evaluate in vitro release mechanisms involved, utilizing different kinetic
models
 To explore applicability of a selected film formulation for delivery through
buccal mucosa for transmucosal delivery
 Thermal and chemical stability evaluation of HME films at different storage
conditions
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2.2.2. Model Drug - Chlorpheniramine Maleate

Figure: 2- 2. Chemical Structure of Chlorpheniramine Maleate

Chlorpheniramine maleate (CLPM) is an antihistamine that is commonly used in the
treatment of various allergic conditions and to provide symptomatic relief from common cold. It
is a low molecular weight amphiphilic drug, thermally stable, water soluble drug and was
selected as a model compound. CLPM is absorbed very well, orally but, undergoes first pass
metabolism thus reducing the amount of drug that is available for systemic circulation. A
controlled release film formulation would ensure continuous release and also aid in avoiding first
pass metabolism.
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2.3. Clotrimazole-Cyclodextrin complex for treatment of vaginal candidiasis
2.3.1. Objectives
The objective of this research was to develop a gel formulation comprising a
Clotrimazole cyclodextrin complex for treating vaginal Candidiasis. The research objectives can
be summarized as follows.
 To perform Phase solubility studies and HPLC analysis of complexes and
understand the type of inclusion complex formed
 Characterization of formed CT-CD complexes utilizing DSC, FTIR, NMR, SEM
and PXRD studies
 To formulate a mucoadhesive gel that can assist in administering CT-CD complex
to the affected region
 In-vitro release comparison studies of gel formulations manufactured from
cyclodextrin CT complexes and, pure CT
 Fungal assays to ascertain the efficacy of formed gels on Candida albicans, C.
krusie and C. glabrata
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2.3.2. Model Drug – Clotrimazole

Figure: 2- 3. Chemical Structure of Clotrimazole

Clotrimazole (CT) is an Imidazole derivative having broad spectrum antifungal
activity and has been used extensively in topical therapy for treating fungal infections. CT has
been to found to be very effective in treating fungal infections, has very few side effects and is
systemically less absorbed. CT is fairly lipophillic and has a water solubility of 0.49 mg/ml. The
one significant drawback of a topical azole therapy is that it requires significant quantity of the
drug and repeated application to maintain a therapeutic concentration. A CD complex can help in
increasing solubility, thereby maintaining optimum concentration for effective management of
candidiasis.
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CHAPTER III
Applicability and Advantages of HME for Solubility Enhancement and as a Processing
Tool for Capsule and Tablet Formulations Using Klucel™ EF and ELF Polymers
3.1. ABSTRACT
The objective of this research work was to evaluate Klucel™ Hydroxypropylcellulose
(HPC) EF and ELF polymers for solubility enhancement of a poorly soluble drug. Ketoprofen
(KPR), a BCS class II drug with poor aqueous solubility was utilized as a model compound.
Preliminary thermal studies performed confirmed formation of a solid solution of KPR in HPC
matrices and aided in establishing processing conditions for HME. Extrudates that were
pelletized exhibited a carrier dependent release, with ELF exhibiting a faster release compared to
the EF polymer. Tablets compressed from milled extrudates exhibited rapid dissolution,
attributed to increased surface area from the milling operation. Addition of Mannitol (MNT)
further enhanced the release by forming micro-pores thereby increasing the porosity of the
extrudates. An optimized tablet formulation constituting KPR, MNT and ELF in a 1:1:1 ratio,
exhibited 90% release in 15 min, similar to a commercial capsule formulation. HPC polymers are
non-ionic, hydrophilic polymers that undergo polymer chain length dependent erosion and
solubilization. The release obtained was carrier dependent and hence such a system can be
utilized to address solubility issues with poorly soluble drugs.

37

3.2. Introduction
Pharmaceutical extrusion processes involves melting and blending of two or more
components by a rotating screw in a heated barrel. The success of extrusion process is defined by
the formation of a miscible, homogenous single-phase system, which remains stable for the
duration of intended storage. HME is a thermally intense process which results in modification
of physico-chemical properties of drug and excipients. The process of melting and mixing of
drug and polymer/s at high temperatures leads to transformation, from which the original solid
phase may never be completely regenerated [117]. These transformations include, but are not
limited to, crystalline to amorphous transformations, solubilization of one component into
another, or formation of immiscible micro crystals in the matrix [118].
Solid dispersions (SD) are utilized in pharmaceutical industry for solubility enhancement
applications. The processing steps involved in manufacturing of SD might induce a physicochemical transformation of the drug. Conversion to a high-energy amorphous form, being one of
them, can impart enhancement in solubility and hence improve bioavailability [13, 119].
However, such high energy forms tend to recrystallize or precipitate out from their
supersaturated solutions and hence stability assessment of such systems is of pivotal importance.
Recrystallization and precipitation in these polymers can be controlled by the use of
crystallization inhibitors [120] or by modifying the release to prevent supersaturation, but, at the
same time maintaining a concentration that would result in bioavailability enhancement [15,
121].
Higher molecular weight grades of Klucel™ Hydroxypropylcellulose (HPC) polymers
are commonly utilized as granulation binders [53], gelling agents or as release retarding agents
[122]. HPC polymers are non-ionic, hydrophilic polymers that undergo dissolution by a swelling
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and erosion driven mechanism. Prodduturi et al reported that the rate of solubilization of HPC is
dependent upon polymer chain length, with longer chain molecules taking more time to swell
and erode [51]. Lower molecular weight HPC’s with smaller chains undergo a faster erosion
process, thus aid in immediate release and enhance solubility of poorly soluble drugs [14]. Being
nonionic, pH independent release can be achieved from matrices manufactured from these
polymers.
Immediate as well as rapid release applications of Klucel polymers were evaluated for
solubility enhancement. Lower molecular weight grades of HPC- EF and ELF, were utilized to
increase the solubility of KPR by forming solid dispersion in a hot melt extruder. HME was used
to intimately mix the components into a homogenous matrix. Ketoprofen (KPR) is a nonsteroidal anti-inflammatory drug commonly used in treatment of pain and inflammation
associated with rheumatic disorders, ankylosing spondylitis, cramps associated with
menstruation and osteoarthritis. Being a Class II drug, dissolution is the rate limiting step for
absorption of orally administered KPR and hence, was used as a model compound [123]. Various
techniques to increase solubilization of KPR have been explored including, formulation of solid
lipid nanoparticles using waxes and lecithin[124], dispersing in pellets using macrogols[125], hot
melt extrusion coupled with a cyclodextrin[126], self-emulsifying drug delivery systems[127]
and lyophilization[128],[129]. Most of these techniques are multiple batch processes that might
also involve the use of organic solvents. Further processing might thus be required to
manufacture a final dosage form that can be administered to a patient.
Preliminary screening studies were performed to evaluate HME feasibility utilizing DSC,
Thermogravimetric analysis (TGA) and hot stage microscopy. The process was optimized and
the extrudates were evaluated for in vitro release, crystallinity and surface morphology.
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Extrudates were prepared into pellets, to be directly filled into capsules or milled to be
compressed into tablets. The extrusion process converted crystalline KPR into an amorphous
form, dispersing the same in a hydrophilic HPC matrix thus, resulting in an increased dissolution
rate. We also have made an attempt to explain dissolution mechanisms that play a significant role
in solubility enhancement. HME was utilized as a process of granulation with the added
advantage of being a solubility enhancement technique. HME also imparted physical properties
to extruded systems that contributed towards better tabletting properties. Amorphous forms tend
to recrystallize on storage and Klucel™ polymers were able to maintain the drug in an
amorphous form for a period of six months.

3.3. Materials
Ketoprofen USP was purchased from Letco medical (1316 Commerce dr. NW, Decatur,
AL, 35601); Klucel™ Hydroxypropylcellulose EF and ELF polymers (HPC) were obtained as
gift samples from Ashland Aqualon functional ingredients (Wilmington, DW); Pearlitol ®
(Mannitol, MNT) was obtained as a gift sample from Roquette (1417 Exchange Street - PO Box
6647, Keokuk. IA 52632). Ac-Di-Sol® and Avicel® 200 were received from FMC biopolymers
(1735 Market Street, Philadelphia PA 19103). Aerosil® was received from Evonik Degussa
Corporation (379 Interpace Parkway, Parsippany, NJ 07054). Magnesium Stearate was
purchased from Mallinckrodt. The chemicals and reagents utilized were of analytical grade and
obtained either from Fisher scientific (Fair Lawn, NJ) or Spectrum chemicals.
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3.4. Methods
3.4.1. Thermal Characterization Studies
3.4.1.1. Thermogravimetric Analysis
PerkinElmer Pyris 1 Thermogravimetric analyzer (TGA) running Pyris manager software
(PerkinElmer Life and analytical sciences, 719 Bridgeport Ave., Connecticut, USA) was utilized
to perform thermo-gravimetric analysis of the samples. 3-4 mg. of the sample was weighed and
heated from 25°C to 200°C at 10°C/min heating rate under an atmosphere of nitrogen and
percent weight loss plotted against temperature.
3.4.1.2. Differential Scanning Colorimetry
Polymer-drug miscibility studies were performed on two component mixtures of
Klucel™ ELF and KPR at increasing concentrations ranging from 10% to 90%. A Perkin Elmer
Hyper Differential scanning colorimeter (DSC) (Perkin Elmer life and analytical sciences, 710
Bridgeport Ave., Connecticut, USA) was utilized. Thermograms were generated by analyzing 23 mg. of the sample in an aluminum pan and heating it from 20˚C to 200˚C at a linear heating
rate of 10˚C/min. Endothermic onset and peak temperature at melting were calculated from the
software. Pyris™ manager software was used to control the instrument and analyze the data
generated. Extruded systems were also evaluated similarly to evaluate crystallinity.
Modulated Differential scanning colorimetric (mDSC) studies were performed on
Thermal Analytics Q1000 mDSC instrument to detect glass transition temperature of amorphous
systems. The samples were heated in hermetically sealed aluminum pans from -30° to 170°C
with a 1°C/min modulation. Ramp rate was set to 3°C/min. The data was analyzed utilizing TA
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Universal Analysis software and glass transition (Tg) temperature calculated by taking the
midpoint of tangents drawn. Two step miscibility studies were performed on physical mixtures
of H1 to H4 formulations. During first step, physical mixtures were heated to melt them and a
second modulated DSC run was then utilized to evaluate phase transformations occurring.
Extrudates were also evaluated for any recrystallization that might have occurred at the end of
storage time points.
3.4.1.3. Hot stage microscopy
Drug and excipient blends were evaluated using a Hot stage microscope and observed
under polarized light for miscibility evaluation and changes in crystallinity. A small amount of
sample was spread on a glass slide and inserted into a hot stage setup. Samples were heated at a
constant heating rate of 10°C/min from 25°C to 200°C and visually observed. Images were taken
continuously at different steps of transformation using a digital camera.
3.4.1.4. Solubility parameters
Hansens 3d solubility parameters for KPR and the polymers were calculated from their
chemical structures using Molecular Modeling Pro™ software (Fairfield, CA) . The solubility
parameters (δt), account for Hydrogen bonding δh, polar interactions δp, and dispersive forces δd
and can be used estimate miscibility between polymers and drug
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3.4.2. HPLC Method
Samples were analyzed on a Waters HPLC and Empower software was used to analyze
the data. The HPLC consisted of a Water 600 binary pump, Waters 2489 UV/detector and
Waters 717plus autosampler (Waters Technologies Corporation, 34 Maple St, Miliford
MA0157). A Waters Symmetry shield C18, 250X4.6mm, 5μm particle size reverse phase
column was used as a stationary phase. Mobile phase comprising 55:45(%v/v),
Acetonitrile:20mMol,pH 4 Phosphate buffer at a flow rate of 1ml/min was used [130]. The UV
detector was set at 256nm wavelength. Extrudates and physical mixtures were analyzed by
dissolving weighed samples in 20ml. of Methanol, filtered and injected at a 20μl injection
volume. Content analysis for tablets was performed by disintegrating the tablets in water and
extracting the drug in methanol prior to injection on an HPLC. All studies were performed as
replicates of six. Samples from dissolution studies were filtered and injected at a 20μl injection
volume similarly.
3.4.3. Formulation –
3.4.3.1 Formulation composition and HME processing
HPC polymers, Klucel™ EF (EF) and Klucel™ ELF (ELF) were used at different drug
concentration levels to evaluate their effect on solubility enhancement of KPR. Polymers and
drug as per Table 3-1, were mixed in a V-cone blender (Maxiblend™, GlobePharma) at 25rpm
for 10 minutes and samples analyzed for drug content and blend uniformity. The blended
material were extruded on a 16mm. Prism Eurolab, ThermoFisher Scientific co rotating twin
screw extruder utilizing a round shaped die to yield extrudate rods. The temperature of the barrel
was maintained at 70°C to 140°C or 100°C to 140°C and screw speeds of 50 or 70 rpm. were
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utilized. The extruded rods were collected on a Teflon coated conveyor belt and pelletized to
yield 1mm. pellets utilizing a pelletizer (Type L-001-9482, Thermoscientific, Stone, UK). They
were stored in Nitrogen filled plastic bags in a refrigerator until further evaluation. The pellets
were evaluated for post extrusion drug content using an HPLC method. The pellets were packed
in a size zero capsules to yield 50mg drug load or milled for tabletting.

Table: 3- 1. Formulation Composition – Pellets

Formulations
H1
H2
H3
H4
H5
H6
H7
H8

Ketoprofen

Klucel™ ELF

Klucel™ EF

Mannitol

33

--

66

--

33

--

33

33

33

66

--

--

33

33

--

33

25

75

--

--

25

37.5

--

37.5

45

55

--

--

45

27.5

--

27.5

44

3.4.3.2. Tabletting
The extruded material was rendered brittle by freezing in a refrigerator and milled in a
Fitzpatrick® mill (The Fitzpatrick company, 832 Industrial drive, IL, USA), using hammers
forward configuration for five minutes. The speed was maintained at 5000 rpm and sieve size
corresponding to USP Sieve#18 used. Tablet blends were prepared as per table 3-2. 10 and 25
mg. strength tablets were compressed on a Mendelco MTP1 tabletting machine using an 8 mm.
biconcave punch, to a final tablet weight of 200 mg. A 50mg tablet was compressed using a
11mm. punch with a composition similar to H4-25T, to be compared to a marketed formulation
of similar strength. 10T and 25T represent tablet strengths 10mg, and 25mg respectively.

45

Table: 3- 2. Formulation Composition – Tablets

Table: 3-2
Excipients (% w/w)

H-10T formulations – adjusted by altering levels of MCC
H1-25T

H3-25T

12.5

12.5

25 (EF)

25 (ELF)

Avicel® 200*

59.5

59.5

Aerosil®

0.5

0.5

AcDisol®

2

2

0.5

0.5

H2-25T

H4-25T/50T

12.5

12.5

12.5 (EF)

12.5 (ELF)

Mannitol

12.5

12.5

Avicel® 200

59.5

59.5

Aerosil®

0.5

0.5

AcDisol®

2

2

0.5

0.5

Ketoprofen
Klucel™ ® EF/ELF

Magnesium Stearate

Ketoprofen
Klucel™ ® EF/ ELF

Magnesium Stearate
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3.4.4. Evaluation of Extruded system- Pellets and Tablets
3.4.4.1. Moisture absorption studies
Extruded pellets were evaluated for percentage moisture uptake using saturated salt
solutions. Pre-weighed plastic weight boats containing around 1 gm. of pellets (n=3) were stored
at 35%, 50%, 65%, 75%, and 96%, RH chambers. Saturated salt solutions of Potassium Sulfate,
Sodium Chloride, Magnesium Nitrate and Magnesium Chloride were utilized to maintain relative
humidity’s of 90%, 75%, 60%, and 50%, respectively. At 0, 2, 4, 6, 7 and 14 days, weigh boats
were taken out, weighed and put back in the shortest possible time. The percent
moisture uptake by the pellets was calculated from the percent weight gain as per the following
equation:

Equation 3.1

3.4.4.2. Microscopy studies
Scanning Electron Microscope (SEM) was used to study surface morphology of extruded
pellets. Samples exposed to dissolution media for ten minutes were also evaluated similarly, to
study morphological changes post dissolution. Samples were sputter coated with gold using a
Hummer® 6.2 sputtering system (Anatech LTD, Springfield, VA) in a high vacuum evaporator.
A JEOL JSM-5600 scanning electron microscope operating at an accelerating voltage of 10kV
was used for imaging. Samples were mounted on adhesive carbon pads placed on aluminum
stubs prior to sputter coating.
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3.4.4.3. In Vitro Release Studies
Extrudates equivalent to 50mg. KPR were filled into capsules and In-vitro release studies
performed on a USP 31 Type I dissolution apparatus. Dissolution media constituting 900ml. of
pH 6.8 phosphate buffer with 1% Tween® 80 added and maintained at 37°C was utilized. Paddle
speed was set at 50 rpm. Samples were collected at every 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, and 5
hours, filtered and analyzed using an HPLC. An equal amount of fresh dissolution media was
added back to the dissolution vessel at each time point. Release profiles were plotted as
percentage release to time.
The dissolution profiles were compared utilizing model independent f2 similarity factor
values, calculated as per the following equation. Dissolution profiles with values between 50-100
are considered to be similar, with 100 being completely identical profiles [131].

{[

⁄

∑

|

| ]

}

Equation 3-2.

3.4.4.4. Powder X-ray diffraction
Powder X-ray diffraction (XRD) studies were performed on a D-8 Advance X-ray
diffractometer (Bruker AXS) equipped with a SolX detector and running DiffracPlus® software.
The generator voltage and current were set to 40KV and 30mA, respectively. The samples were
scanned from 10° to 40°, 2Θ values with 0.05° ramp at 3 sec/step.
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3.4.5. Stability testing
Samples were stored in closed glass bottles and evaluated for physical and chemical
stability for a period of 6 months utilizing DSC, mDSC, XRD and chemical assay. Refrigerated,
25°C/60%RH and 40°C/75%RH conditions were utilized. The studies were performed utilizing
replicates of six. In-vitro release studies were performed on tablets stored at different stability
conditions. The release profiles were compared based on calculated similarity factor values.
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3.5. RESULTS AND DISCUSSION
3.5.1. Thermal Characterization
3.5.1.1. Thermo Gravimetric analysis
Thermal degradation was not observed with the excipients, however, KPR started to
degrade at around 200°C (Figure 3-1). Extrusion conditions were maintained well below the
degradation temperatures to maintain the stability of all the component systems. KlucelTM
polymers are hygroscopic polymers and exhibited a 2-3% moisture uptake and hence were dried
prior to extrusion.

Figure: 3 - 1. TGA spectra of KPR and Polymers
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3.5.1.2. Hot Stage Microscopy
A hot stage microscope was utilized to replicate temperatures inside an extruder and
observed under a polarized light microscope (PLM). Polarized light aids the differentiation of a
crystalline form from a glassy/amorphous form [132, 133] and was hence utilized in this study.
Crystalline KPR started to melt at around 97°C and converted to a molten form. HPC softened
around 130°C and on melting completely, was found to be miscible with KPR (Figure 3-2.a).
Similar transformations were observed in H2 formulations for HPC, KPR and MNT. However,
MNT which melted at 170°C started to recrystallize back at 70°C (Figure 3-2.b). The hot stage
microscope confirmed the formation of a miscible amorphous system of KPR - EF mixtures.
KPR-ELF systems exhibited similar results.

a: HSM-PLM images of H1 formulation

b: HSM-PLM images of H2 formulation
Figure: 3-2. (a-b) HSM images of H1 &H2 Formulations
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3.5.1.3. Miscibility Studies
At all the concentrations evaluated KPR and HPC were found to be miscible with each
other. The onset temperature and endothermic melting peak of KPR were comparatively lower to
that of pure KPR until a 60% drug loading. This suggested partial solubilization of KPR by HPC
during the first heating step (Figure 3-4) [134]. KPR melting peak was not observed in second
reheating step which confirmed formation of an amorphous KPR. H1-H4 physical mixtures as
well as pure KPR were similarly evaluated on an mDSC. Pure KPR exhibited a Tg around
0.85°C. HPC has been reported to have a Tg in between -25˚C to 0˚C which is dependent upon
percent humidity [53]. Extruded formulations exhibited Tg in the range of 2˚C to 4°C suggesting
this Tg to be that of a miscible single phase solid solution of KPR and HPC.
Based on results obtained from thermal studies it was confirmed that KPR forms a solid solution
with HPC polymers and were found to be miscible with each other. HME processing
temperatures were set as per data obtained from DSC and hot stage studies.
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Figure: 3 - 3. Polymer drug miscibility studies- DSC thermograms first heating step

Figure: 3 - 4. Polymer drug miscibility studies- Onset and Peak Temperatures obtained
from DSC thermograms
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3.5.1.4. Solubility parameters
Solubility parameters have been used to predict the miscibility of drugs and polymers in
solid dispersions. Components with similar δt values suggest formation of a miscible system as
the energy of mixing from intramolecular interactions is balanced with the energy from
intermolecular interactions. Greenhalgh et al demonstrated that components with Δδt < 7Mpa1/2
are likely miscible and Δδt > 10Mpa1/2 to be immiscible [135]. Difference in δt values for drug
and polymers, and between polymers was less than 7Mpa1/2 suggesting that they are miscible
with each other. A δt value of 18.9 and 20.8 Mpa1/2 were obtained for KPR and HPC,
respectively hence it can be assumed that the two components are miscible with each other as
obtained Δδ values are less than 7 Mpa1/2. Thermal miscibility studies further support this.
3.5.2. Hot melt Extrusion Process
Klucel™ polymers, owing to their thermoplastic and thermostable nature have been
utilized to form HME matrices earlier by Repka and co-workers [51, 122]. HPC polymers are
semi crystalline polymers that soften over a wide range of temperatures from 100° to 140°C and
have been extruded from 120°C to 170°C[136],[137]. HME is a usually carried out at conditions
that would either melt or soften the drug, or the excipients used. Additionally, plasticizers are
employed to decrease viscosity, reduce the torque on the extruder and increase efficiency of the
blending process. Earlier studies performed with HPC HF, a higher molecular weight grade of
HPC, report the advantages of using plasticizers and also plasticizing effect of drugs [137]. KPR
which melts at 97°C has been known to provide plasticization effect for the melt [130]. A similar
effect was observed with our formulations and hence extrusion could be carried out at lower
temperatures and higher screw speeds. Lower molecular weight polymers such as Klucel™ EF
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and ELF, due to smaller chains, have comparatively lower viscosity and hence exert lesser
torque. We were able to significantly decrease the extrusion temperature for ELF polymer and
formulations with 45% drug loading to a temperature of 100-120°C.
HME conditions such as barrel temperature and screw speed were optimized for
maximum yield and were set according to observations made from thermal studies. A
temperature setting of 100°C-140°C and 75rpm screw speed resulted in formulations with
maximum yield. KPR on melting exhibits a tacky nature and cannot be extruded on its own
without a matrix. Crowley et al tried to evaluate KPR-polyethylene oxide extrudates at a 30%
level but were unable to extrude due its tacky nature [130]. HME performed on H7-H8 (45%
drug load) exhibited slightly similar behavior as observed by Crowley et al, but could be
extruded at a lower temperature of 110 to 120°C. Addition of mannitol significantly aided the
extrusion and pelletizing process in these formulations. The extrusion conditions employed
maintained MNT in a crystalline state (confirmed by DSC studies), provided a necessary
backbone for the pelletization and milling operations.
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Figure: 3 - 5. Effect of processing conditions on Post Extrusion drug content
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3.5.3. Evaluation of Pellets
3.5.3.1. Moisture Absorption Studies
HPC are known hygroscopic polymers and hence moisture absorption studies were
performed to evaluate the effect of moisture on HME extrudates. H1 & H3 pellets absorbed
approximately 12% and 19% moisture, respectively, at 90% RH. H2 and H4 pellets absorbed
approximately 6% and 9% moisture, respectively, at 90% RH (Figure 3-6-a,b). Pellets
manufactured with ELF polymer showed comparatively higher moisture gain than EF pellets
owing to increased hydrophilicity of ELF. H2 & H4 exhibited decreased moisture absorption
relative to the H1 and H3 formulations and was attributed to lower hygroscopicity of MNT.
Though such conditions are not routinely encountered, but these experiments suggest a possible
weight gain in the extrudates and the need for proper packing material. Lower humidity
conditions during manufacturing and moisture barrier packing during storage can effectively
minimize moisture uptake.

57

a. Moisture uptake study - H1 and H2 formulations

b. Moisture uptake study – H3 and H4 formulations
Figure: 3 - 6. (a-b) Moisture uptake study – H1 to H4 formulations
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3.5.3.2. Polarized light microscopy of Extrudates
Thin sections of extrudates were observed under polarized light at ten times
magnification. H1 and H3, pellets exhibited a characteristic birefringence pattern observed in
polymers on extrusion. Phase separation and crystalline character were not observed confirming
formation of a single phase, miscible, amorphous system. H2 and H4 formulations, exhibited a
crystalline characteristic owing to presence of Mannitol (Figure 3-7).

Figure: 3 - 7. PLM images of extruded pellets – H1, H2, H3, and H4
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3.5.3.3. Scanning Electron Microscope
Formulations manufacturing KPR and HPC exhibited a smooth surface suggesting a
completely miscible single phase system. Formulations comprising MNT exhibited a similar
smooth texture which was dispersed with crystalline mannitol. Images 3.6.a-e represents H5, H3,
H4, H7 and H8, formulations respectively. Extrudates representing higher drug loading
formulations, H7 and H8, exhibited smooth surface which were interspersed with fissures. These
fissures or cracks might have been formed during the cooling phase of extrusion process. HPC is
a long chain, viscoelastic polymer that can expand or contract owing to flexibility of its polymer
chains. A small molecule such as KPR lacks such viscoelastic characteristics and apparently
might have resulted in unequal contraction during cooling, resulting in development of cracks in
the matrix. It was also observed that on extrusion these formulations exhibited decreased dye
swelling owing to decreased polymer levels.
3.5.3.4. Differential Scanning Calorimetry studies
DSC and mDSC studies performed on extruded pellets confirmed formation of a single
phase solid solution of KPR and EF/ELF. A single Tg and a crystalline peak for MNT were
observed in the thermograms confirmed the physical state of component systems.
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Figure: 3 - 8. a-e SEM images of pellets manufactured using Klucel™ ELF polymer

61

3.5.4. In Vitro Release Studies
3.5.4.1. In Vitro release studies - Pellets
Formulations manufactured utilizing ELF polymer exhibited faster release in comparison
to EF pellets. A release of 52.7±0.6% and 74.5±1.6% in one hour for H1 and H3 formulations,
respectively, was observed. Formulations with mannitol, H2 and H4, released 85.8±3.6% and
88.5±1.5%, drug respectively. The extruded formulations, H2 to H8, had a comparatively faster
release than an equivalent un-extruded KPR, (Figure 3.9). H1 formulation comprising EF
polymer did not show a significant improvement over physical mixture blends (f2 value of 62).
However, addition of mannitol in H2 as well as H4 resulted in an improvement in release.

Figure: 3 - 9. In Vitro release of EF and ELF pellets
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HME involves mixing of molten drug and polymers resulting in formation of a solid
solution or dispersion of drug in a polymer matrix. Such dispersions, due to their inherent
advantages, have been utilized to increase solubility of poorly soluble drugs [119]. In our work
Klucel™ polymers were able to disperse amorphous KPR at a molecular level in a hydrophilic
matrix. HPC enhances the dissolution process by increasing the wettability, surface area and also
aids in stabilization of amorphous KPR [118]. Hydroxylpropylcellulose polymers undergo
dissolution via a swelling and erosion driven mechanism which is dependent upon chain length
[50]. Longer chain polymers require a longer time to erode and hence result in slower release.
Klucel™ ELF and EF polymers have a comparatively lower molecular weight and undergo faster
erosion, resulting in immediate release of KPR. Amongst the polymers used, ELF matrices
exhibited a faster release owing to smaller polymer chain length and molecular weight.
Yuasa et al and Prodduturi et al reported similar polymer chain length dependent release of
poorly soluble drug from different grades of HPC [37, 50, 138]. The factors – increased surface
area, amorphous form and a hydrophilic matrix contribute towards an increase in dissolution
rate. In addition, Mannitol due to its high solubility, creates micro-pores in the matrix by
solubilizing at faster rate and enhances release significantly [139, 140]. During HME process
molten polymer tends to densify on being pushed through a die - resulting in decreased porosity
[41]. MNT might have also compensated for this decrease in porosity, as it is non-compressible
agent compared to rest of components.
Hydrophilic polymer based solid dispersions has gained interest over the last decade due
to a growth in the number of poorly soluble compounds reaching development phase. However,
this technology comes with a caveat that formulations performing well in vitro, may fail in vivo
testing. Carrier mediated or drug related phase conversion or precipitation, occurring in these
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formulations has been reported to be the reason for such unexpected release. SDs rely on
hydrophilic polymers to increase wettability and an amorphous form of the drug to increase drug
solubility in the media. These polymers tend to solubilize at a faster rate leaving behind a super
saturated drug which might result in solution mediated phase conversion [16]. Sheen et al
observed that solid dispersion using melt technology did not result in an increased bioavailability
and suggested that this could be due to precipitation of the poorly soluble drug in gastric media
[141]. Dinunzio et al observed that formulations which exhibited a slower release over a
prolonged period of time resulted in better bioavailability by preventing super saturation and
recrystallization of Itraconazole [121]. Similarly, Law et al concluded that a slower release
would benefit bioavailability as the precipitated crystalline form would require more media to
undergo dissolution [15]. Thus a slower release, still in the domain of immediate release, might
actually contribute towards increased bioavailability and better stability for SD. Klucel polymers
with a wide range of molecular weights and non-ionic character can be rightly selected to tailor
such release that is carrier dependent and also prevent precipitation or recrystallization.
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3.5.4.2. Effect of Drug loading
The dissolution profiles of pellets extruded at different drug loads of 25%, 33% and 45%,
were compared (Figure 3-10). Formulations H7 and H9 with 25% and 45% KPR, respectively,
had similar release profiles as H3 (33% KPR) formulation (Table: 3-3). It was observed that an
increase in KPR concentration decreased its release in one hour from 74.5±1.6% to 65.7±3.5%,
for H3 and H9 formulations, respectively. A similar trend was observed with Mannitol and ELF
formulations, H4, H6 and H8. H4 formulation with an equal distribution of KPR, ELF and MNT
(1:1:1) released the drug in the least amount of time. In all the formulations studied, pellets
manufactured utilizing ELF exhibited a faster release but at higher drug loading of 45%, no
significant improvement in the release of KPR was observed.
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Figure: 3 - 10. In vitro release of KPR pellets at different drug loading
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Table: 3- 3. Effect of drug loading on in vitro release, f2 values

Excipients
ELF

Formulations
H3

H5

H7

74.5±1.6

75.50±1.1

65.7±3.5

H3-H5

H3-H5

H5-H7

f2

56

55

44

ELF+MNT

H4

H6

H8

88.5±1.5

68.3±4.0

75.1±3.0

H4-H8

H4-H6

H4-H8

43

39
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% Release in 1 h

% Release in 1 h

f2
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As per Higuchi’s matrix model, release from a matrix occurs by dissolution and diffusion
of one component through the other through formation of channels in the matrix [142]. Due to
difference in solubility, component with higher solubility solubulizes at a faster rate leaving
behind component with comparatively lesser solubility [143]. Tortuosity defines the
irregularities in the channels created during dissolution and has a significant effect on the
diffusivity of a drug. At higher drug loading (45%), less soluble KPR forms infinite or
continuous clusters thereby increasing tortuosity, preventing surface penetration and thereby
dissolution [144]. In formulations such as H4, HPC and MNT undergo rapid solubilization
forming channels resulting in decreased tortuosity and increasing diffusivity of the dissolution
media. A similar decrease in release has been observed in extruded matrices by Crowley et al
and Zhang et al which was attributed to decreased penetration of dissolution media [74, 145].
Amorphous forms utilized in SDs can revert back to their crystalline forms or may
precipitate out on exposure to dissolution media. An increase in drug loading resulted in a
decreased release and a drop in bioavailability for Ritonavir (RTR) based solid dispersions. This
drop in release was attributed to a localized phase conversion of amorphous RTR to a crystalline
form [15]. These transformations in the solid state can be minimized by the use of appropriate
polymers and recrystallization inhibitors. However, solution mediated drug transformations
require specific techniques to maintain super saturation. KPR exhibited miscibility of
approximately 60% in DSC studies without undergoing any recrystallization on cooling. We
assume that there might be a localized recrystallization of KPR on contact with the dissolution
media, thus affecting release. This phase conversion, if any, can be considered to be solution
mediated and not carrier mediated.
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3.5.4.3. SEM evaluation of pellets at different drug loading
SEM was utilized to evaluate morphological changes occurring in pellets exposed to
disso media. SEM images of H5 (25% KPR) pellets exhibited a significant change in
morphology on dissolution which can be attributed to soluble ELF and MNT (Fig. 3B-I). It was
observed that H5 (Fig 3B-I), on dissolution, exhibited significant changes in morphology. The
dented appearance was formed due to rapid solubilization of hydrophilic excipients by an inward
moving solvent front. The soluble polymers formed channels allowing media to enter the matrix.
On comparison of SEM images of pellets, post dissolution samples exhibited a smoother surface
in contrast to an uneven texture formed during extrusion, supports surface dissolution of HPC
(Figure. 3.11, I-IV).
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Figure: 3 - 11 (I-IV) SEM images of pellets manufacture using Klucel™ ELF polymer –
Post exposure to dissolution media
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3.5.4.4. In Vitro release studies – Tablets
Extrudates were milled and compressed into tablets with the addition of MCC as a direct
compression vehicle and Ac-Di-Sol® as a disintegrant. Tablets exhibited faster release in
comparison to pellets and followed a similar rank order (Figure 3-12). HME exerts compressive
forces on molten material that results in densification, decreased porosity and surface area. These
problems were addressed by milling the material and using a super disintegrant to disperse the
same. Tablets manufactured from H4 matrices exhibited rapid release in comparison to rest of
the formulations (Table 3-4). H3-25T showed a slower release when compared to other tablet
formulations. ELF polymer, being more plastic forms a denser and less porous compact on being
compressed thus slowing the release [53]. This increased compactibility also resulted in
increased tensile strength and has been further detailed in the tablet characterization section.
Table: 3- 4. % In vitro release from tablets at 25mg strength in 30 min.

Formulation

% Release in 30 min

H1-25T

77.2±0.5

H2-25T

76.3±2.6

H3-25T

58.6±3.2

H4-25T

88.7±6.3
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Figure: 3 - 12. In Vitro Release profiles of tablets at 25mg. strength

H4 pellets comprising Klucel ELF polymer were utilized to manufacture tablets to be
compared to a marketed KPR capsule. Tablets were compressed to a 50mg strength utilizing
11mm. round biconcave punch to a tablet weight of 400mg. The percentage drug release in
fifteen minutes was 92.8±4.4% and 87.0±1.3%, respectively, for H4-50T and marketed
formulation. We were able to successfully utilize extrusion process to manufacture immediate
release tablet formulations of KPR utilizing Klucel polymers. The milled matrices utilized in
tablet formulations exhibited faster release in comparison to pellets due to particle size reduction
of extrudates. The dissolution profiles are presented in the Figure 3-13.
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Figure: 3 - 13. In Vitro Release comparison to a marketed capsule formulation
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3.6. Stability Testing –Pellets and Tablets
Physico-chemical analysis was performed on pellets that were stored at room and
accelerated stability conditions for a period of six months. HME process converts crystalline
drug to an amorphous form which tends to recrystallize on storage. Increased temperatures and
presence of moisture further enhances this phase conversion. mDSC and DSC studies were
utilized to analyze the physical state of the drug and excipients post storage. mDSC confirmed
the presence of an amorphous form of the drug based on the glass transition temperatures (Tg)
and lack of crystalline melting peaks (Figure 3-14). All the extruded pellets were found to be
chemically stable for a period of six months at the storage conditions tested. The percent drug
remaining at the end of last time point was more than 95% after six months of storage at
40°C/75% RH.
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Tablets
The crystallinity was evaluated utilizing XRD studies. KPR remained in an amorphous
form in XRD spectra. Crystalline peaks of KPR at 2θvalues corresponding to 14.2, 18.4, 22.9
[126, 130] were absent in tablets mixtures at the end of storage time points (Figure 3-12). Tablets
remained chemically stable in all the formulations for a period of six months. Tablets stored at
40°C/75% RH showed comparatively slower release compared to initial release profiles. H4-50T
Tablets stored at 25°C/60% RH had similar profiles to their initial release profiles (Figure 3-10).
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Figure: 3 - 16. XRD images of H4-25T tablets: 6 months storage time point
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CONCLUSION
Multi-particulate dosage forms such as pellets, with a proper dispensing device, can be
utilized to answer some of the unmet needs in the pharmaceutical industry [146]. Conventional
pelletization techniques utilize solvents and are typically batch processes. HME is a non-solvent
continuous process and hence is considered a faster technique [147] for the manufacture of
multi-particulate delivery systems.
We were able to successfully utilize Klucel™ Hydroxypropylcellulose polymers as HME
matrix formers, granulation and solubility enhancing agents. Feasibility evaluation of HPC was
performed and its advantages in forming and maintaining solid solutions detailed. Hot melt
extrusion technology is being extensively explored to increase solubility of poorly soluble drugs.
However factors such as high temperatures, drug-excipient stability, phase separation or
conversion are essential for long term stability. We also explored the advantages of HME
process as a technique that can be used as a technique with added an added benefit of increased
tabletability of the matrices. The formulations were chemically and physically stable for a period
of six months under accelerated stability conditions. The release profiles obtained were similar to
the marketed formulation. Klucel™ polymers have been typically used as binders in granulation
and as control release polymers. We were able to explore the possibility of utilizing these
polymers as immediate release excipients and also as stability imparting polymers. A
formulation approach to form multi particulate delivery systems is outlined and with proper
delivery device, could be adopted for ‘dose as per need’ dosage forms. HME is a versatile tool
which can be modified for wider applications and a suitable polymer expands this applicability
significantly.
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CHAPTER - IV

Characterization of Tabletting Behavior of Blends Manufactured From Hot Melt Extruded
Matrices
Abstract
Hot melt extrusion technology was utilized to form amorphous solid dispersions of a
poorly soluble drug, Ketoprofen and Klucel™ EF/ELF polymers. The extrusion process allowed
for intimate mixing of components, which on cooling formed an indiscernible homogenous
matrix. In addition to increase solubility, matrices exhibited unique properties that affected
tabletting behavior of the blends. Compactibility, Tabletability and Compressibility profiles were
generated and compared for HME matrices as well as physical mixtures. Conventional tablet
characterization techniques were also performed simultaneously on tablets manufactured on an
automated tabletting machine. A Texture Analyzer was utilized to measure the work involved
during tabletting breaking and extent of tablet deformation before breaking. Tablets
manufactured from extruded matrices were found to be more plastic and underwent a significant
change in morphology prior to breaking.
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4.1. Introduction
Granulation is a standard unit operation commonly employed to increase particle size,
maintain content uniformity, improve tabletting properties and address problems such as poor
flow [148]. Traditional granulation techniques include blending, activation of binders and drying
steps to remove solvents, prior to milling to form granules. However, limitations with these
methods include– limited drug loading, solvents and sharp granulation end points. HME has
been explored as a granulation alternative due to various reasons. It is a continuous process with
no or very less solvent requirement, the agitation brings about intimate mixing of components
and if required, heat can be applied to further speed up the drying process. HME was used to
manufacture high drug loaded formulations, which were otherwise not feasible through
conventional granulation techniques [38, 149]. Also, formulations manufactured from HME
exhibited better tabletting properties in comparison to tablets obtained from roller compaction or
wet granulation. Utilization of twin screw extruders as a continuous granulation tool has been
explored by Keleb et al. Water was used to activate the binders and the extrudates cut into tablets
[150]. HME was utilized to enhance tabletting properties of Isomalt, which was used as a filler
excipient [70].
In this work, HME was utilized to manufacture solid dispersions of KPR to enhance its
solubility. The metering sections and die exert considerable amount of pressure on material
which results in compaction and hence a decrease in porosity. Milling operations aid in
disintegration of extrudates and increase surface area brought about by particle size reduction.
Thus, tabletting allows for dosage forms that can easily disintegrate and disperse the extrudate
material, aiding in faster release. As mentioned earlier, HME imparts physico mechanical
properties to extrudates that results in a significant improvement in tabletting properties. Lower
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molecular weight grades of HPC have been utilized at 1-2% level as granulating agents and at
30-40% level as release modifiers due to their matrix forming ability [53]. Also, HPCs have been
found to prevent capping tendency in tablets manufactured on high speed tabletting machines
[151]. Smaller chain polymers have less of an elastic relaxation in comparison to longer chain
polymers and aid in reducing capping.
Compactibility profiles of extrudates and un-extruded blends were generated and
compared to evaluate effect of HME on tabletting. Tablets were also evaluated using
conventional testing and using a texture analyzer to understand the dynamics involved during
tablet breaking. These mechanistic studies aid in better understanding of the effects of polymers
and processing conditions on tabletting properties.
4.2. Materials and Methods
The following chemicals were used as obtained: Microcrystalline cellulose (MCC;
Avicel® PH101) from FMC biopolymers (Newark, DE), Dicalcium phosphate (DCP; DiTab ®)
from Stauffer Chemicals (Tampa, FL), Pregelatinized starch (Lycatab®) and Mannitol
(Pearlitol®) from Roquette America Inc., (Keokuk, IA), Lactose monohydrate (lactose;
Pharmatose®) from DMV-Fonterra excipients (Germany), and Magnesium stearate from Alfa
Aesar (Ward Hill, MA); Hydrochloric acid (HCl), Sodium hydroxide (NaOH), 3% v/v Hydrogen
peroxide (H2O2) and Orthophosphoric acid were obtained from Fisher Scientific (Fair Lawn,
NJ). HPLC grade water was freshly prepared in the laboratory by Nanopure systems (Barnstead,
Dubuque, IA). All solvents utilized in the study were of analytical grade and obtained from
Fisher Scientific (Fair Lawn, NJ).
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4.2.1. Excipient compatibility studies
Tablet excipient compatibility was performed by preparing 1:1 binary mixtures of
commonly used tabletting excipients and drug, evaluating them for a period of 2 weeks. The
blends were exposed to 60°C heat in open bottles and analyzed utilizing a DSC at initial, 7 and
14 day time points. DSC method, mentioned earlier, was used to evaluate the stability of the
samples by comparing thermograms at different time points. The following excipients were
utilized for this study:

Xylitol, Isomalt, Mannitol, Primojel, Crospovidone, Emcompress,

Avicel-102, Sugartab, Magnesium Stearate, Sodium Stearyl Fumarate, Glycolys and Ac-Di-Sol®.
4.2.2. Tablet characterization
Standard characterization tests were performed on tablets manufactured from extruded
material. The thickness and diameter of the tablets was measured using a micrometer.
Disintegration testing was performed on a Dr. Schleuniger Pharmatron USP (Schleuniger
Pharmatron Inc., 1 Sundial Ave., Manchester, NH 03103) disintegration apparatus. Friability
testing was performed in a friabilator (Roche friabilator). A Varian VK200 (Agilent
Technologies, 13000 Weston Parkway, Cary, NC, 27522) hardness tester was utilized to test the
hardness of tablets. Each tablet was placed diametrically between the anvils of the instrument
and the force required to break the tablets measured. Six replicates were tested and the values
averaged out. Tensile strength was calculated from hardness values utilizing the following
equation. F is the force measured at tablet failure or breaking, d and h are the diameter and
thickness of the tablet, respectively.

Equation 4-1.
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4.2.3. Compaction profiles
Compaction profiles were generated for extruded and un-extruded KPR formulations as
per their definitions[152]. A hydraulic Carver press (Fred Carver, Menomonee, WI) was used to
compress tablets at different compaction pressures ranging from 50MPa to 500MPa using an 8
mm. punch. Tablets were tested for hardness and, tensile strength calculated. True density
measurements of the tabletting blends were performed using a Micromeritics Helium
pycnometer (AccuPyc II 1340, Norcross, GA 30093). Porosity measurements were made by
calculating the true density of the tablets and utilizing it to calculate the percent solid fraction (S)
in the tablet. The percent porosity (Ɛ) was calculated using the following equation:
Equation 4-2
Tabletability is represented by a plot of tensile strength versus compaction pressure,
Compactibility by a plot of tensile strength versus porosity and Compressibility by a plot of
porosity versus compaction pressure [153].
4.2.4. Texture analyzer
TA-XT Plus Texture Analyzer (Texture Technologies Corp., Scarsdale, NY) was used to
calculate the hardness, work of failure and percent change in diameter at tablet failure. A TA-8
ball probe was used to exert diametrical force on a vertically placed tablet. The test probe
travelled at 2 mm sec-1 until the tablet surface was detected at 0.05 N, after which the probe
travelled to a 3mm distance. A 10kg load cell was used to register the force exerted till the point
of tablet breaking.
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Figure: 4 - 1. Texture Analyzer plot
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4.3. RESULT AND DISCUSSION
4.3.1. Tablet – Excipient Compatibility studies
Excipient stability studies are important to assess long term stability of a formulation.
Though the concentrations used and the temperature the studies are performed do not replicate
the actual storage conditions, their aim is to maximize any interactions that might occur that
would suggest drug degradation. No interactions were observed with the excipients used (Figure
4-1). KPR peak exhibited a slight deviation in KPR:Avicel and KPR:Isomalt mixtures. Isomalt
melts around 100°C and loss of moisture from Avicel might have resulted in such deviations and
do not suggest incompatibilities. Thermograms generated for KPR with Magnesium Stearate
showed some interactions as the melting peak of KPR had shifted. Stearates have been found to
be incompatible with KPR and also other drugs [154]. At the concentrations used and presence
of KPR in extrudates such incompatibilities might not affect the stability of the drug.

85

Figure: 4 - 2. Excipient compatibility studies - DSC thermograms, Post storage of 14 days
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4.3.2. Compactibility Profiles
Compactibility, Tabletability and Compressibility of HME tablets and tablets
manufactured using un-extruded blends were studied. HME results in a physical transformation
of drug and excipients which influences tabletting behavior. Compressibility, Compactibility and
Tabletability profiles as described by Tye et al were utilized to understand the effect of melt
extrusion on tabletting [155].
Compressibility is defined as an ability of material to undergo a reduction in volume as a
result of an applied pressure. Compressibility profiles did not exhibit any difference among
extruded formulations (Figure 4-2). However, extruded blends were found to be more
compressible compared to un-extruded formulations. The increased ability to form compacts can
be attributed to increased plasticity of the extruded material [156].

Figure: 4 - 3. Compressibility profiles of extruded matrices
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Compactibility profiles can be used as a measure or tendency of a material to be
compacted and is plotted as change in tensile strength to percentage porosity (Figures 4-3). It can
also be defined as how good a compact can be prepared on tabletting of the blend. Un-extruded
T1, T2 formed better compacts at lower compaction pressures but exhibited capping at higher
compaction pressures. Un-extruded formulations manufactured utilizing ELF polymer did not
exhibit any capping for (T3 and T4) even at higher compaction pressures. Similar observations
were made by Martino et al [151]. H3-25T tablets were plastic in nature and as they did not
break during hardness testing, profiles could not be generated. EF and ELF retained their
compaction properties post-extrusion. H3-25T tablet formulations had a plastic nature and did
not break under the hardness testing and hence tensile strength could not be measured. Of all the
tablets compared H4-25T was found to be more compactable than the remaining formulations
owing to the presence of ELF which is a lower molecular weight grade of HPC. Addition of
Mannitol might have decreased the compactibility of H4-25T in comparison to other
formulations.
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Figure: 4 - 4. Compactibility profiles of extruded matrices

With a decrease in molecular weight of HPC, compactibility and plasticity increase with
a consequential decrease in elasticity [53]. Smaller chain length ELF polymer hence exhibits less
elastic recovery, higher plasticity and undergoes a greater deformation forming better compacts
on being compressed. Also, HME converts the drug and HPC to an amorphous form leading to a
subsequent increase in surface area for bonding between the tabletting excipients [156]. This
transformation could be a reason for increased tabletting properties of extruded systems. Also,
the smaller chains in ELF might have contributed towards a lesser elastic recovery and hence no
capping was observed in tablets at higher compaction pressures for un-extruded tablets T3-25T –
T4-25T. Un-extruded formulations were utilized as controls and behaved similarly or slightly
better than extruded formulations in these tests.
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Tabletability profiles are plotted as tensile strength vs. compaction pressure are useful
tools to establish tabletting behavior of formulation blends. The extruded systems had similar
tabletting properties as un-extruded blends. The extruded formulations did not exhibit an in
tensile strength after a certain point. Among all the formulations tested, H4-25T exhibited better
compactibility and tabletability (Figure 4-4).

Figure: 4 - 5. Tabletability profiles of extruded matrices
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4.3.3. Tablet characterization tests
Tablets manufacture on a tabletting machine passed all the standard tests such as weight
variation, friability and disintegration testing. Hardness testing was performed on tablets
compressed at same compaction pressure. H1-25T, H2-25T, H3-25T and H4-25T exhibited
hardness values of 99.8±7.7, 79.9±3.0, 108.6±2.6 and 88.5±5.5 Newton, respectively, (Figure 44). Addition of mannitol resulted in a decrease in hardness values. Mannitol, a crystalline
excipient, on compression undergoes plastic deformation whereas HPC has a viscoelastic
character that aids in holding the matrix together. HPC is considered a good binder in
conventional tableting operations and is used extensively. A similar behavior was observed in
HME extruded matrices, with Klucel™ ELF having better performance than EF.
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Figure: 4 - 6. Tablet Hardness evaluation – Extruded vs. Un-Extruded
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4.3.3. Hardness evaluation utilizing Texture analyzer
The classical hardness testing registers force required for a tablet to fail or break) under
an applied diametrical force, between two anvils. However, the test fails to register the dynamics
involved prior to point of failure and hence, a texture analyzer was utilized to analyze the same.
Tablets were compressed at a constant compression force and evaluated utilizing work of failure
(Wf) and percent change in diameter (Cd) at tablet failure. The area of the plot - force to distance
travelled, can be utilized to calculate work done during diametrical breaking of a tablet and is
represented as work of failure. The peak of the plot denotes the force at breakage and can be
simultaneously used to calculate the distance travelled by the probe from the point of contact to
the distance causing a break. During testing a probe exerts a diametrical force at a constant speed
onto the tablet and load cell registers the change in force to distance displaced by the probe.
Tablets manufactured from extruded matrices were more resistant to breaking in comparison to
un-extruded tablets. The extent of deformation, as measured by the percentage change in
diameter and work of failure was higher for extruded tablets (Figure 4-5). These observations
correlated with the data generated from compaction profiles.
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Figure: 4 - 7. % Change in Diameter on compression

Figure: 4 - 8. Work of failure at tablet failure
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CONCLUSION
Hot melt extrusion is a versatile technology that can be adapted easily to manufacture a
variety of dosage forms with slight modification. HME using Klucel polymers imparted
interesting characteristics to extrudates that aided in improvement in release, as well as tabletting
properties. Klucel™ ELF polymers formed better compacts and were also able to prevent a
capping tendency in un-extruded tablet formulations. Extruded matrices imparted a plastic
behavior to the tablets and were found to better resist deformation, or breaking. These findings
represent a significant role in improving handling, packaging and coating operations after
tabletting.
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CHAPTER V
Custom – Controlled Release Formulations Utilizing Polymer Blends And Hot Melt
Extrusion For A Water Soluble Drug

5.1. Abstract
The aim of this project was to investigate the effect of sustained release polymer blends
on the release of a highly water soluble model drug, Chlorpheniramine maleate (CLPM).
Eudragit® RSPO and Klucel™ EF were utilized to control the release of CLPM from
POLYOX™ N10 matrices. Thermogravimetric analysis, Differential scanning calorimetry, and
solubility parameters were utilized to evaluate stability and miscibility of component systems for
hot melt extrusion. Hot melt casting method was utilized as a preliminary screening method to
evaluate the effect of polymer blends on release. HME films manufactured were evaluated using
near infra-red chemical imaging to study the effect of particle size on distribution of the drug and
polymers in the matrix. Polymer blends of RSPO and HPC were found to be better in attaining
sustained release than when used alone. C7 formulations comprising 20% HPC and 25%RSPO
released 76±5% drug in two hours whereas HPC and RSPO alone released the same amount of
drug in 30 min and 1 hr respectively. Increase in concentration of HPC significantly delayed the
T80% release from 6 hr to 29 hr at 30% and 55% concentrations. Release profiles were fit using
least squares regression to evaluate the effect of polymer concentration on release. A 90%
regression was obtained suggesting the applicability of polymer blends in attaining a tailored
release.
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5.2. Introduction
Polymeric matrices have often been used to alter drug release, so as to bring about
immediate or prolonged therapeutic effect. Many methods have been mentioned in the literature
that bring about modified release such as, using polymers in tablets that form a matrix in situ
[157] or use of polymeric coating methods [158]. Hydrophilic as well as hydrophobic polymers
have been extensively used to control drug release from pharmaceutical dosage forms. These are
either water soluble of cellulosic esters or insoluble acrylic polymers. Based on the release
intended, polymers can be selected to render a zero order, pulsatile, sigmoidal release, or targeted
release profiles [159].
Cellulosic ether derivatives such as Hydroxypropyl Methyl cellulose (HPMC),
Hydroxypropyl Cellulose (HPC), Hydroxyethyl cellulose (HEC), and Ethyl Cellulose (EC) are
frequently utilized for modified release applications. These are the most preferred polymers for
controlled release applications due to their swelling as well as compressible characteristic that
aids tabletting. HPC polymers are available in different grades with higher molecular weight
grades commonly utilized as gelling agents or as release retarding agents [122]. HPC and HEC
polymers, owing to their stability and release characteristics have been utilized in HME
processes to manufacture modified release formulations [36, 37, 47, 48]. Eudragit RSPO
polymers are copolymers of ethyl acrylate, methyl methacrylate and methacrylic acid ester with
quaternary ammonium groups that render these polymers permeable, which otherwise, are water
insoluble [86]. Eudragit® RSPO and RLPO have been utilized to control release of indomethacin
[43] and Chlorpheniramine maleate [160] from solid solutions manufactured via HME. Also,
HME processing was better able to retard release in comparison to traditional granulation or
direct compression methods.
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Manufacture of such polymeric systems typically employs coating processes, the
functionality of which depends upon thickness and uniformity of the polymer film. End point
determination of coating processes is usually assessed by weight gain or by a time consuming
disintegration test [161]. Film coating performed on a fluid bed processor or pan coating may
lead to non-uniform coating leading to failure of such dosage forms due to formation of channels
[158]. Another common method used involves manufacture of matrix tablets using gel forming
agents [162].
Polymer blends are utilized to improve formulation characteristics, release profiles or to
stabilize formulations. These blends can also be used to achieve tailored release profiles by using
appropriate concentrations of water soluble and insoluble polymers [163, 164]. Prodduturi et al
utilized a blend of HPC and PEO polymer blends to improve physico-mechanical properties of
Clotrimazole films for transmucosal delivery [51]. Kalivoda utilized a polymer blend to stabilize
Fenofibrate recrystallization from HME matrices without effecting the release profiles [165].
Polymer blends have also been used as targeted delivery systems, to deliver active ingredients to
the lower intestine [166]. Another application involves miscible polymer blends to tailor release
dependent upon time constituting chrono therapeutics [167].
Traditional methods such as, film coating, cannot be effectively used to manufacture
coating mixtures with polymer blends due to many issues related with such a blend [163]. They
suffer from drawbacks such as requirement of appropriate solvent that can dissolve all of the
polymers and also a possibility of flocculation in aqueous dispersions prior to coating [163].
HME is a non-solvent continuous process that can be effectively utilized to homogenously mix
polymers and drugs into a single matrix. The intense mixing operation results in single phase
system that can hold its integrity even on breaking or crushing, and address issues with film
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coated tablets. HME polymer blends can also be used to maintain physical and chemical stability
of the active in addition to imparting mechanical strength.
This research has attempted to evaluate the advantages of polymer blends to control the
release of a soluble drug. Hot melt extrusion was utilized as a processing technique due to its
inherent advantages compared to traditional coating methods. A preliminary evaluation was
performed utilizing a hot melt casting method and formulation compositions were established.
Homogenous distribution of polymers was confirmed using a chemical imaging and in vitro
release studies. Stability assessment was also performed on the films. Higher molecular weight
Polyethylene oxide polymers have been utilized as rate controlling or modifying agents in HME,
whereas lower grades such POLYOX™ N10 have been used to enhance solubility, due to its
hydrophilic character and also to act as plasticizers[45]. In this study PEO was used as a matrix
former and as a control formulation for CLPM release from such matrices.

5.3. Materials
Chlorpheniramine maleate (CLPM) was purchased from Spectrum chemicals (769 Jersey
Ave. New Brunswick, NJ,). Klucel™ Hydroxypropylcellulose EF polymer (HPC) was obtained
as a gift sample from Ashland Aqualon functional ingredients (Wilmington, DW); Eudragit
RSPO (RSPO) was obtained as a gift sample from Evonik Degussa Corporation (379 Interpace
Parkway, Parsippany, NJ 07054), POLYOX™ N10 was obtained from Dow pharmaceutical
ingredients. The chemicals used were of analytical grade and obtained from either Fisher
scientific or Spectrum chemicals.
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5.4. Methods
5.4.1. Thermal Characterization
Pyris 1 Thermogravimetric analyzer (TGA) controlled Pyris manager software
(PerkinElmer Life and Analytical Sciences, 719 Bridgeport Ave., Connecticut, USA) was used to
perform thermogravimetric analysis of samples. Drug and excipients were evaluated for thermal
stability at high temperatures. 3-4 mg. of the sample was weighed and heated from 25°C to
200°C at 10°C/min heating rate under an atmosphere of nitrogen. Loss in weight as a measure of
change in temperature was plotted using Pyris software to generate thermograms.
Differential scanning colorimetry (DSC) was performed to detect crystallization changes
occurring in the drug. A Perkin Elmer Hyper Differential scanning colorimeter (DSC) (Perkin
Elmer Life and Analytical Sciences, 710 Bridgeport Ave., Connecticut, USA) was used to
analyze the samples. Thermograms were generated by analyzing 2-3 mg. of the sample in an
aluminum pan and heated from 20˚C to 200˚C at a linear heating rate of 10˚C/min. Endothermic
onset and peak temperature at melting were calculated from the software. A second scan, after
cooling, was performed to evaluate recrystallization of CLPM utilizing similar testing
conditions. Pyris manager software was used to control the instrument and analyze the data
generated. Stability samples were also evaluated at different time points for crystallinity.
Polymer-drug miscibility studies were performed on two component mixtures of drug
(10% to 30%) and polymers Eudragit® RSPO or POLYOX™ N10 or Klucel™ EF. A second
heating step was utilized to evaluate for crystallinity of CLPM. Extruded systems were also
evaluated utilizing DSC.
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5.4.2. Solubility parameters
Hansens 3d solubility parameters for CLPM and the polymers were calculated from their
chemical structures using Molecular Modeling Pro™ software (Fairfield, CA) or referenced from
the literature. The solubility parameters (δt), account for Hydrogen bonding δh, polar interactions
δp, and dispersive forces δd and can be used to estimate miscibility between polymers and drug.
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5.4.3. Formulation Composition
Formulation composition was designed keeping the drug concentration constant at 10%
loading. PEO was used as a base polymer and its concentration was adjusted to accommodate the
controlled release polymers. Eudragit® RSPO and Klucel® EF (HPC) polymers were utilized as
release modifying agents to control the dissolution of CLPM. Formulations C1, C2 and C3 were
used as control formulations. HPC concentration was altered at 10%, 20%, 30% and 55%
keeping the concentration of the RSPO constant at 25% in C5, C7, C9, & C11 formulations
respectively. Similarly, RSPO concentration was varied at 15%, 25%, 35% and 55% keeping the
concentration of HPC at 20% in formulations C4, C7, C8 & C10 respectively.

TABLE: 1
Formulations
Drug
Eudragit

C1

C2

C3

C4

C5

C6

C7

C8

C9

10

10

10

10

10

10

10

10

10

10

10

-

25

-

15

25

25

35

25

55

25

-

-

20

20

10

20

20

30

20

55

®

RSPO
Klucel™ EF
PEO
Antioxidants

25
(RLPO)
20

C10 C11

87.8 62.8 67.8 52.8 52.8

42.8

42.8 32.8 32.8 12.8 12.8

2.2

2.2

2.2

2.2

2.2

2.2

2.2

2.2

Table: 5- 1. Formulation composition of films
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2.2

2.2

2.2

5.4.4. Hot Melt Casting method for films
A hot melt cast (HMC) method was utilized to manufacture films as a preliminary
screening method. Blends were prepared as per Table 1 and mixed uniformly in a mortar and
pestle. Weighed samples of mixtures equivalent to 50 mg. drug were weighed, dispersed into a
heated dye placed over a brass plate, compressed and melted at 140° to 160°C for a period of 10
minutes. In vitro release and content uniformity studies were performed on patches utilizing an
HPLC method.
5.4.5. Hot Melt Extrusion
Polymers and the drug were mixed in a V-cone blender for ten minutes and samples
analyzed for drug content uniformity. The blended material was extruded on a
ThermoScientific® 16mm co-rotating twin screw extruder utilizing a flex lip die to yield films.
The extruded films were conveyed onto a chill roll to cool and collected in nitrogen filled plastic
bags. The temperature profile of the barrel was maintained from 80°C to 130°C and 50rpm speed
was used. Patches were cut from different sections of the films were evaluated for post extrusion
content and content uniformity.
5.4.6. HPLC analysis
Chemical analysis of samples was performed on a Waters HPLC and Empower software
was used to analyze the data. The HPLC consisted of a Water 600 controlled binary pump,
Waters 2489 UV/detector and Waters 717plus autosampler (Waters Technologies Corporation,
34 Maple St, Miliford MA0157). A Waters Symmetry shield C18, 250mmX4.6, 5 μm particle
size reverse phase column was used as a stationary phase running a mobile phase constituting
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55:45 (%v/v) Methanol: 20 mMol. pH 4 buffer. The UV detector was set at 256nm wavelength.
Samples for content analysis were analyzed by dissolving weighed samples in 20ml. of
Methanol, filtered and injected at a 20μl injection volume.
5.4.7. Particle Size Distribution of Polymers
The particle size analysis of the polymers was performed utilizing sieve analysis as per
the method stated in USP 31. USP standard sieves 25, 35, 40, 50, 70, 80 and 100 were utilized.
Particle size evaluation was performed to evaluate any demixing of blends in the extruder.
5.4.8. Near Infrared Chemical Imaging spectroscopy
Near infra-red chemical images (NI-CI) of HME films were collected on a Sapphire IM
NIR Spectral Imaging System (Spectral Dimensions, Inc., Olney, MD). The imaging system
consists of a liquid crystal tunable filter (LCTF) coupled with a NIR sensitive focal plane array
(FPA) detector. The NIR light reflected (via diffuse reflectance) from the samples to the detector,
was passed through a LCTF, and was imaged onto the indium-gallium-arsenide focal plane array
with 256×320 pixels. Images were recorded from the 1400 to 2450nm wavelength at 10nm
intervals (105 frames). Images were analyzed by ISysIM software (Spectral Dimensions, Inc.,
Olney, MD), each spectrum in the corrected reflectance (R) data cube was converted to
absorbance by calculating the logarithm of the inverse of the reflectance (log(1/R)). Each
spectrum in the absorbance cube was further differentiated with the Savitzky–Golay second
derivative filter with a length of 11 points (100 nm) and a third polynomial order. Pure polymers
RSPO, HPC, PEO and the drug CLPM were used to construct the library.
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5.4.9.1. In vitro Release studies and Release mechanisms
In vitro release studies were performed using a Hanson SR8+ dissolution test system
according to USP 31 apparatus 5, paddle over disk method. Dissolution testing was performed
using 500 ml. pH 6.8 buffer as a dissolution media maintained at 37°C with the paddle rotation
speed set at 100 rpm. Patches equivalent to 50 mg. drug were cut from extruded films. HMC
patches were prepared as single units and hence were used as such.
Data obtained from in vitro release studies was fit to different release models to evaluate
release mechanism involved. First order, zero order, Higuchi, and Korsemeyer Peppas models
were utilized. Higuchi’s matrix release model was used to calculate time taken for 80% (T80%)
and 50% (T50%) drug release from the linear section of the release data. Data points
corresponding to a correlation value of 0.99 were used for calculations. Coefficient of ‘n’ was
calculated from equation 4; n=0.45, 0.45<n<0.89 and 0.89<n<1.0 relate to Fickian diffusion,
non-Fickian diffusion and zero order transport, respectively. A high intercept value k for a
Koresmeyer fit may suggest a burst drug release from the matrix. The following equations were
utilized to model the release.

Zero order

(

First order

)

(

-------Equation 5-1

)

-

√

Higuchi matrix model

Koresmeyer peppas model

(

)
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---------Equation 5-2

---------Equation 5-3

---------Equation 5-4

5.4.9.2. Statistical analysis
The effect of concentration and type of polymer on the release represented by T 80% and
T50% values were fit using JMP 9.0.2 (2010 SAS Institute Inc.) software to understand
correlation. A surface response curve and P values were calculated to evaluate effect of each
parameter on the responses.
5.4.11. Stability testing
Films were stored at 25°C/60%RH and 40°C/75%RH for a period of six months and
evaluated for drug content and crystallinity utilizing a DSC instrument. In vitro release testing of
C7 formulation were performed on films stored at 4°C, 25°C/60%RH and 40°C/75%RH at 0 and
3 months duration. Similarity factor was calculated to compare the release profiles. A calculated
similarity factor of 50 or above is considered to be similar profiles and below as dissimilar.
5.4.12 Powder X-ray diffraction
Powder X-ray diffraction (XRD) studies were performed on a D-8 Advance X-ray
diffractometer (Bruker AXS) equipped with a SolX detector and DiffracPlus® software. The
generator voltage and current were set at 40KV and 30mA, respectively. The samples were
scanned from a range of 10° to 40°, 2Θ values at 0.05° ramp and 3 sec/step.
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5.5. RESULTS AND DISCUSSION
5.5.1 Thermal Analysis
Thermal degradation was not observed for any of the polymers utilized however, CLPM
exhibited weight loss at around 200°C suggesting thermal degradation. Other excipients utilized
in this study did not show any degradation till 250°C. Extrusion conditions were maintained
below these temperatures to prevent any thermal degradation of drug or polymer.

Figure: 5-1 TGA Thermograms of CLPM, RSPO, HPC, PEO and C7 formulations
Physical mixture
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5.5.2. DSC Miscibility studies
CLPM is a crystalline compound with a melting point of 137±0.2°C and endotherm onset
temperature of 137±0.2°C. A crystalline peak of CLPM was observed in physical mixture of
CLPM with RSPO and HPC in the initial run but was absent in second reheating step. CLPM
exhibited miscibility with all the polymers utilized and converted to an amorphous form after
melting. A Glass transition for amorphous RSPO was observed at around 67°C. Experiments
were carried out at three different drug loads of 10%, 20% and 30% with PEO to understand
miscibility of PEO and CLPM as an endotherm peak was not observed at 10% drug load. An
endotherm onset temperature of 110±1°C and melting peak of 129±.0.8°C was observed at 30%
drug load, suggesting miscibility [134].

Figure: 5- 2. DSC thermograms of Physical mixture of CLPM at 10% drug load
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5.5.3. Solubility parameters calculation
Solubility parameters have been used to predict the miscibility of drugs and polymers in
solid dispersions. Components with similar δt values suggest formation of a miscible system as
the energy of mixing from intramolecular interactions is balanced with the energy from
intermolecular interactions. Greenhalgh et al demonstrated that components with Δδt < 7Mpa1/2
are likely miscible and Δδt > 10Mpa1/2 to be immiscible [135]. Difference in δt values for drug
and polymers, and between polymers was less than 7Mpa1/2 suggesting that they are miscible
with each other. Table 5-2 lists the individual values (in bold) and the difference values (Δδ).

Units CLPM
Mpa

HPC

RSPO

PEO (δt=21.7)

1.8 (Δδ)

4.4 (Δδ)

0.9 (Δδ)

2.6 (Δδ)

0.9 (Δδ)

1/2

CLPM

22.6 (δt)

HPC

--

20.8 (δt)

RSPO

--

--

18.2 (δt)

PEO

--

---

--

3.5 (Δδ)
21.7 (δt)

Table: 5-2. Solubility parameter values for CLPM and excipients
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5.5.4. Hot Melt Casting
A hot melt casting (HMC) method was employed as a screening technique prior to the
extrusion process to evaluate the feasibility and study the effect of polymer blends to render
control release. Casting methods allow for faster screening of excipients and their effect on
release profiles, at the same time utilizing very less amount of the drug [168, 169]. However it
suffers from the drawback that melts are not mixed and hence homogenous distribution of
components is not as likely as a melt extrudate.
Amongst formulations comprising pure polymers N10 (C1) and blends - HPC (C2) and
RSPO (C3), respectively, RSPO exhibited a pronounced effect on retarding the release (Fig. 53). C7 formulation comprising RSPO 25% and HPC 20% significantly retarded the release in
comparison to C1, C2 and C3 patches. HPC and RSPO were able to retard the release better
when used together than when used separately, exhibiting a synergistic effect. An increase in
concentration levels of RSPO further in formulations C4, C7 and C8 did not result in retarding
the release any further. A similar trend was observed in HMC films prepared utilizing HPC in
formulations C5, C7 and C9 formulations.
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Figure: 5-3. In vitro release comparison of HMC patches C1, C2, C3 (n=3)

Figure: 5-4 In vitro release comparison of HMC films – a. Effect of RSPO concentration
b. Effect of HPC concentration (HMC films – denoted by ‘M’)
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As per observations made from HMC studies, C1, C2, C3 and C7 films were extruded
and compared. HME formulations exhibited a faster release with PEO, in comparison to HPC
and RSPO polymers. PEO polymers have been used to enhance solubility of poorly soluble
drugs previously due their hydrophilic character and ability to form solid dispersions [170,
171]. Also, CLPM converts to an amorphous form resulting in increased solubility. RSPO
retained its controlled release characteristic. As earlier observed C7 formulation exhibited the
slowest release among extruded formulations. Overall HME films exhibited faster release in
comparison to HMC films.

Figure: 5-5. In vitro release comparison of HMC and HME films (n=3)
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5.5.5. Effect of Particle size on Content and release profiles – C7 films
HME process involves melting and mixing of drug and excipients in a heated barrel
brought on by a rotating screw. The agitation provided by the screw elements allows for the
material to be uniformly mixed, conveyed forward and be discharged through a die. However,
patches sectioned from extruded films of the same formulation, exhibited deviations in content
assay and release, and could not be reproduced from one batch to another. An example of
patches form C7 formulation has been presented in Fig. 5-6. Blend uniformity confirmed by
analyzing pre- and post-extrusion drug content confirmed uniform distribution of CLPM.
A possible explanation towards this deviation could be demixing of polymers inside the
barrel or incomplete mixing of the blends. The EF polymer utilized for these studies was a coarse
grade with an average particle size above 100 μm and the rest of the polymers, including the
drug were of lower particle size, below 100 μm Fig. 5-7). This could have resulted in demixing
or aggregation inside an extruder leading to irreproducible release profiles. Also, HPC melts at a
higher temperature allowing it to remain as a softened powder and thus improper mixing might
have occurred within the melt as the rest of the components would be in a molten state. HPC
matrices undergo a swelling and erosion driven mechanism to release the drug from an enclosed
matrix. HPC might not have formed a uniform layer around the CLPM resulting in formation of
channels in the matrix. Similar observations were reported by Verhoeven et al who observed
unpredicted release with coarser grade of Xanthan gum [172] . All of the polymers were sieved
to a standard particle size closest to the drug, and extruded in two different batches. The profiles
were identical to each other as per similarity factor values proving the hypothesis. In addition
C7-EFX films manufactured using sieved polymers and EXF, finer grade of HPC EF, also
exhibited identical profiles.
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Figure: 5-6. In vitro release profiles of C7 HME Formulation utilizing un-sieved polymers

Figure: 5-7. Particle Size analysis of polymers used to manufacture C7 formulation
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5.5.6. Near Infrared Chemical Imaging
Near IR chemical imaging allows for spatial recording in addition to spectral assessment
of a sample. Spatial recording can be used to map distribution of individual components on the
surface by comparing it with pure compounds [173]. Images were generated with the contrast
depending upon the absorption of a particular wave length characteristic to the drug or polymer.
Analysis was performed as a qualitative assessment alone, though this technique can also be used
for qualitative assessment.
Images obtained were consistent with the dissolution profiles and drug content analysis
data, suggesting a homogenous distribution of all the components in the matrix. C7-EF (sieved
polymers) and C7-EFX formulations prepared using Klucel® EF and Klucel® EXF (fine grade
HPC), respectively, exhibited similar distribution of drug and polymers. CLPM was
demonstrated to be uniformly distributed in all of the films (Fig.5-8). The C11 film manufactured
using RSPO at 55% concentration and unsieved EF polymer exhibited segregation and formed a
continuous phase as seen in Figure 5-8b. These films exhibited rapid release initially due to
formation of channels in the matrix but later on exhibited sustained release. As per these
observations all formulations were manufactured using sieved polymers.
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Figure: 5-8. NICI images of films with distributions based on a) CLPM, b) HPC, c) RSPO
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5.5.7. In vitro release studies – HME films
Hydrophilic polymer matrices during dissolution undergo hydration forming a viscous gel
that continuous to erode releasing the drug. The release is controlled by the extent of polymer
swelling, polymer relaxation, diffusion through the gel layer and polymer erosion [174]. The rate
at which this process occurs is dependent upon the molecular weight and chain length of the
polymer. HPC polymers undergo a similar swelling and erosion based mechanism to release the
drug [50]. Prodduturi et al utilized different molecular weight grades of HPC to obtain control
release of a poorly soluble drug [37].
Eudragit RSPO is a hydrophobic acrylic polymer which on exposure to water swells and
forms a gel matrix. This property increases the diffusional path length a drug molecule has to
travel to enter the dissolution media and thus retards the release of the drug. The quaternary
ammonium components undergo solubilization creating channels that allow the drug to diffuse
into the dissolution media[175]. Higher concentration of these polymers creates a more viscous
gel that increases the tortuosity and slows the release of the active.
Addition of HPC, in the C7 formulation resulted in a delayed release with T50% and T80%
values of 0.75 and 2.2 Hr., respectively. Hydrophilic polymers PEO and HPC dissolve on contact
with the dissolution media, forming channels in the matrix resulting in higher T50% values. As
the polymers hydrated further during dissolution, retarded release characterized by higher T80%
values was observed. RSPO was able to prevent erosion of HPC matrix and by forming a gel.
HPC might have created a tortuous path for by occupying channels in the RSPO gel. Both the
polymers work synergistically, effectively preventing erosion and increasing diffusional paths, in
retarding the release.
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Drug release was reduced when RSPO and HPC were used simultaneously in C7 formulation
and were similar to observations made from the hot melt cast films. However and increase in
concentration of RSPO did not result in a significant difference in C2, C4, and C7 formulations
based on f2 values as the release profiles were almost similar (f2>50). Increase in RSPO levels
from 25% to 35% and 55% resulted in significant retarding of release in formulations C7, C8,
and C10 respectively (f2<50). Effect was more prominent in T80% release suggesting the time
taken for the polymers to undergo hydration and gelling phenomena in altering release.

Figure: 5-9. In vitro release profiles of HME films – Effect of RSPO concentration (n=3)
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Figure: 5-10. Time taken for 50% and 80% Release – Effect of RSPO polymer

Addition of RSPO at a 25% concentration to HPC formulations resulted in a prominent
decrease in release (f2<50). Also, effect of increase in HPC concentration from 10% to 55%
resulted in a significant decrease of CLPM from the matrices in C3, C5, C7, C9, and C11
formulations. Decrease in release was more prominent at higher concentrations of RSPO and
HPC, as observed in C8 to C11 formulations. In the C11 films, a significant effect on T80%
values was observed. In formulations C8 and C9, time taken for 80% release was 4.8h and 6h,
respectively. Although it is difficult to understand the release mechanism involved, it can be
hypothesized that presence of RSPO resulted in a decreased erosion rate of HPC, thereby
resulting in controlled release.
Effect of increase in HPC concentration resulted in better retardation of release at higher
concentrations. Release from C4, C5, C7 formulations followed Fickian trans polymer diffusion
119

as per calculated n-values and fit to Higuchi matrix model, suggesting a dominant effect of
RSPO in controlling release in these formulations. The additional formulations followed
anomalous release mechanism resulting from diffusion as well as erosion of the polymers. As
stated earlier, drug release from RSPO occurs through diffusion from a gel matrix and from HPC
through a mechanism of swelling and erosion.

Figure: 5-11. In vitro release profiles of HME films – Effect of HPC
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Figure: 5-12. Time taken for 50% and 80% Release – Effect of HPC polymer

HPC and PEO being hydrophilic, might have formed channels in RSPO matrix resulting
in faster release in C5 and C7 formulations initially (T50% values). However as the polymers
undergo hydration, release slowed down as characterized by higher T80% values. This effect
was more prominent in C8, C9 and C11 formulations, which took 4.8, 6, and 29 hours
respectively, to release 80% CLPM (Fig.5-13).
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Figure: 5-13. In vitro release comparison of HME films manufacutred using HPC+RSPO
polymers
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Table: 5-3. Release models and coefficients
Release
models

HME
films

Higuchi
diffusion

Slope

Regressio
n
Koresmeye
r

Intercept
% Release
Slope (n)

T50% Release (in hours)

C2
RS

C3
HP

C4
RS1
5

C5
HP1
0

C7
C8
RS25 RS3
HP2 5
0

42.3
5

72.7
9

57.4
1

69.11

37.48

0.88

0.98

0.98

0.99

1.8

1.90

C9
HP3
0

C10
RS5
5

C11
HP5
5

19.5
5

14.21

12.1
7

14.74

0.95

0.84

0.64

0.79

0.92

1.67

1.76

1.66

1.7

1.51

1.28

80

-

63

47

57

46

50

33

19

0.53

-

0.56

0.75

0.51

0.42

0.40

0.35

0.51

0.4

0.1

0.66

1.05

0.75

1.2

1.0

2.4

5

1.0

0.5

1.5

2.05

2.2

4.8

6.0

27.4

29.0

T80% Release (in hours)
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5.5.8. Statistical analysis of release profiles
T50% and T80% values obtained from dissolution data were fit to a least squares model
using JMP software and evaluated. The various parameters such as effect of concentration and
type of polymers (RSPO, HPC, and PEO) were found to exhibit a significant effect on release
(p<0.01). A linear relationship was observed with respect to T50% and T80% values to change
in concentration of RSPO and HPC. A regression coefficient of 91.25 and 94.54 was obtained
from the actual to the predicted plot suggesting accuracy with which the model could be used to
predict the effect of concentration of polymers on T50% and T80% values, respectively. Such
linearity can be utilized to modify concentration of polymers to achieve a targeted release
profile. All factors–concentration of RSPO, HPC, and PEO were found to exhibit a positive
effect on retarding the release based on coefficients, with PEO exhibiting the least effect. HPC
exhibited a comparatively larger effect on release compared to RSPO.
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Figure: 5-14. Response surface plot showing effect of concentration of HPC and RSPO on
T50% release
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5.5.9. Stability studies
Films stored at 4°C, 25°C/60%RH and 40°C/75%RH did not exhibit any recrystallization
or degradation for a period of three months. At the last time point tested, drug concentration
remained at 97% however an assay was not performed to analyze concentration of degradants as
CLPM was only used as a model compound. CLPM remained in an amorphous state which was
confirmed by DSC chromatograms and XRD scans of the films (Fig.5-15).

Figure: 5-15. XRD Spectra of C7 films and excipients stored at different storage conditions
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Figure: 5- 16. DSC thermograms Films -3 month’s stability
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In vitro release profiles of C7 formulation stored at 4°C, 25°C/60%RH and 40°C/75%RH
for a period of 3 months exhibited similar release when compared to initial profiles. Calculated f2
values for films stored at 4°C, 25°C/60%RH and 40°C/75%RH were 79, 54 and 59, respectively,
suggesting similarity in profiles.

Figure: 5- 17. In vitro release profiles of C7 formulation post storage
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5.6. CONCLUSION
This study successfully demonstrated that a controlled release film formulation
for a water soluble drug utilizing polymer blends and hot melt extrusion could be formulated.
The release mechanisms involved in such a matrix system were studied and its correlation to
drug release established, paving the way for custom controlled release formulations. Klucel® EF
and Eudragit® RSPO polymer blends have been demonstrated to modulate a water soluble drug
release, such that the pharmaceutical scientist may design formulations with desired release
profile for ones API.
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CHAPTER VI

Clotrimazole-Cyclodextrin complex for treatment of vaginal candidiasis
6.1. ABSTRACT
The aim of this study was to prepare a Clotrimazole (CT) complex with 2-hydroxypropyl
beta cyclodextrin (HPCD) to enhance its solubility and release characteristics, for better
management of vaginal Candidiasis. The CT complex was prepared by a co-precipitation
method. The phase solubility study was performed to assess the complexation behavior of CT
with HPCD. The continuous dilution method was used to determine stereochemistry between the
drug and the complexing agent using Nuclear magnetic resonance spectroscopy. The complex
was further characterized by DSC, SEM and FTIR methodologies. Complexes were formulated
into gels using a cold gelation method and characterized for in vitro release and antifungal
activity. The phase solubility curve was an AL-type, indicating formation of a 1:1 complex
between the drug and HPCD. The association constant and complexing efficiency were 44.6 M-1
and 0.009, respectively. FTIR and NMR spectra confirmed the stereochemistry of a 1:1
complexation between CT and HPCD. Also, SEM photomicrographs of the complex showed a
distinctly different crystalline shape, compared to drug. Additionally, release studies
demonstrated a sustained release of Clotrimazole from the gel complex for more than 24 h in
acetate buffer (pH 5.5) with the complex providing improved release. Complexes exhibit better
fungistatic activity than un-complexed Clotrimazole.
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6.2. Introduction
Vulvovaginal Candidiasis (VCD) or Vulvovaginitis is a common vaginal infection
affecting 75% of women at least once in their lifetime. The affliction is most commonly caused
by Candida albicans and hence the name Candidiasis. 10-20% of infections are sometimes
associated with non-albicans species, of which C.glabrata is the dominant one[176]. It is
characterized by inflammation of the vagina and vulva, most often caused by bacterial, fungal, or
parasitic agents. The vaginal ecosystem consists of a healthy interrelationship between micro
flora, its metabolic products, estrogen and pH levels. This ecosystem is continuously challenged
by various factors that may sometimes lead to proliferation and colonization of certain micro
flora. Usage of antibiotics, immunosuppressive conditions such as AIDS, and diabetes mellitus
may directly or indirectly alter the natural balance leading to Candidiasis.
VCD can be treated through systemic and topical applications of azole antifungal agents
of which Clotrimazole (CT) is the most common one. All azoles given orally or topically are
associated with a dramatic symptom relief in 24-48 hours [177]. CT is an imidazole derivative
having broad spectrum antifungal activity and has been used extensively in topical therapy for
treating fungal infections [178]. It is the first line, broad spectrum antifungal agent for
prophylaxis as well as treatment of oral and vaginal candidiasis [178]. A 7-day topical azole
therapy is more effective than single dose oral therapy in treating severe infections [179].
Clotrimazole is a highly lipophilic in nature (logP 4.1) and has poor aqueous solubility
(solubility=0.49 mg/L) [180, 181] and slow dissolution in water [180]. It is available in the form
of creams, vaginal tablets and lotion over the counter in United States. Due to CT’s poor
solubility, repeated applications are required to maintain a therapeutic concentration. Multiple
daily doses of conventional formulations result in poor patient compliance. Also, conventional
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drug delivery systems (exemplified by tablets, creams, gels, pessaries, and foams) suffer from
poor retention in the vaginal tract, as they are rapidly dislodged in a short time, by the selfcleansing action of the vaginal tract [182]. Furthermore, the efficacy of these preparations is
however limited due to their short residence time in the genital tract.

Figure 6-1. Structure of Clotrimazole (CT)

These two problems are compounded in impairing the therapeutic efficacy of
clotrimazole formulation in the treatment of vulvovaginitis. It is suggested that vaginal therapy
can be significantly improved if a delivery system can maintain high concentration of the drug at
the site of administration for a prolonged period. Various methods have been described to
improve the solubility of clotrimazole such as using microcapsules[183], thermosensitive
gels[184],

liposomes[185],

suspension

with

hydroxyl-propyl

methyl

cellulose

in

nanosphere[186] and using hot melt extrusion [51]. Complexation with cyclodextrins and/or its
derivatives is one of the techniques that can be utilized to increase intrinsic solubility of
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clotrimazole. Investigators have reported complexation of Clotrimazole with beta-cyclodextrin
[187, 188], gamma-cyclodextrin [189] which resulted in increased solubility.
Cyclodextrins (CD) have a wide variety of applications in the pharmaceutical industry
and have been used as rate controlling agents, solubilizers and taste masking agents. FDA
considers CD as GRAS (generally regarded as safe) excipients. Modified CD such as 2Hydroxypropyl-β-cyclodextrin (HPCD) are considered as Inactive Pharmaceutical Ingredient and
have also been used in parental formulations in high concentrations. CD derivatives have been
effectively utilized to increase the solubility of less water soluble azoles such as Miconazole
[190], Itraconazole [191], and Sertaconazole [192] and have been very found to be successful .
The present study details a formulation approach utilizing the complexation of CT with
2-Hydroxypropyl β-cyclodextrin to increase its solubility and hence efficacy. Cyclodextrins
(CD) have been known to enhance solubility by incorporating the drug in the lipophilic core of
the CD molecule. Complexes were characterized using various methods to confirm type of
association between HPCD and CT. Thus, formed CT-HPCD complex were formulated as gel
formulations and evaluated for in vitro release and antifungal evaluation.
Gels can present several advantages over other formulations like increased
bioavailability, safety, versatility, being economical and are also more preferred by women over
other vaginal applications [193, 194]. That being the reason most of the current research is
directed at development of bio adhesive gels [195]. Various novel polymers have been designed
to increase bio adhesiveness but are marked by inadequate activity due to lack of maintenance of
optimum therapeutic concentration. Bioadhesive misoprostol delivery through the vagina has
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been found to be more efficacious than when taken orally [195]. Sustained release formulations
of Miconazole [196] were found to be useful in decreasing the number of applications.
6.3. Materials
Clotrimazole (CT), 2-Hydroxypropyl-β-Cyclodextrin (HPCD), Hydroxy Propyl Methyl
Cellulose (HPMC), Tween -80, Peirecenet pleated Snake skin dialysis membrane (Thermo
Fisher Scientific Inc., Rockford, IL USA, distilled water, Acetonitrile.
6.4. Methods
6.4.1. HPLC method
A modified HPLC method was used for the analytical estimation of Clotrimazole in the
complexes and the gels. A waters 600 pump with a dual wavelength waters 2489 UV detector
was used for the HPLC analysis. Phenomenex Luna C18 column with 150x4.60 mm dimensions
and inner particle size of 5µm was used as a stationary phase. The mobile phase constituted a
mixture of Acetonitrile (ACN) and pH 5.5 buffer of 50 mM strength at a ratio of 65:35. UV
detector was set at 210 nm wavelength and Empower software was used to analyze the
chromatograms. The gels were analyzed by dissolving them in 50:50, ACN: Water mixture and
then filtered using a 0.45 μ filter. The dissolution samples were centrifuged to remove any
particulate matter, filtered using a 0.45µm filter and injected into the column. All the standards
and samples were injected at 20 µl volume.
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6.4.2. Phase Solubility Studies
The phase solubility studies of CT were performed using shake flask method described
by Higuchi and Connors[101]. Excess of drug was added to different known concentrations of
HPCD and allowed to equilibrate. Concentrations ranging from 0 to 50 mM, in increments of 5,
were prepared in glass vials using double distilled water. The vials were kept under constant
shaking at 70 rpm for 7 days at 25ºC. Excess drug allowed for saturation equilibrium to be
reached. After 7 days, drug solutions were collected, filtered and the supernatant analyzed using
HPLC for amount of CT dissolved.
6.4.3. Characterization of Complexes
A 25 mM solution of CT and HPCD were prepared by dissolving in Ethanol and let to
equilibrate for 7 days. Thus obtained solution was filtered and then dried using a vacuum dryer at
30º-40ºC for 24 h. The formed complex was then characterized using different techniques such
as Differential Scanning Calorimetry (DSC), Nuclear Magnetic Resonance Spectroscopy
(NMR), Fourier Transform Infra-Red Spectroscopy (FTIR), X-ray diffraction (XRD) and
Scanning electron Microscopy (SEM).
Complexes were also prepared by physical mixing, kneading methods which employed
slight amount of solvent to make a slurry and solvent evaporation or co-precipitation method.
6.4.3.1. Differential Scanning Colorimetry
A Perkin Elmer Hyper Differential Scanning Calorimetry was used to analyze the CT,
HPCD and CT-HPCD complexes. The samples (n=3) were hermetically sealed in aluminum
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pans and heated over a range from 25º C to 250º C at 10ºC min-1 . The obtained spectra were
analyzed using Pyris manager software.
6.4.3.2. Fourier Transform Infrared Spectroscopy (FTIR)
Infra-red spectroscopy was performed on a Perkin Elmer FTIR- Paragon 500
spectrometer and the scans were analyzed using Spectrum Ver. 5.0.2 software. The CT, HPβCD,
and CT-HPCD complex were analyzed by incorporating them with KBr in a ratio of 1:100 and
compressing them as pellets. The pellets were scanned from 600 to 4000 cm-1 wave number eight
times and spectrum averaged to reduce the noise.
6.4.3.3. Nuclear Magnetic Resonance Spectroscopy (NMR)
A Bruker AV 400MHz Nuclear magnetic spectrometer having a 3mm nalorac dual proton
optimized probe and running on topspin 2.0 software was used to perform NMR analysis. Pure
CT, HPCD and the mixtures of two in different mole fractions at 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8
and 0.9 were dissolved in deuterated dimethyl Sulfoxide and left to equilibrate overnight.
Samples of 600 μl volumes were then taken in 3mm NMR glass tubes and analyzed. The peak of
DMSO was taken as a reference peak. Mestrenova software was utilized to analyze the data.
6.4.3.4. Powder X-ray Diffractions studies
Powder X-ray diffraction (XRD) studies were performed on a D-8 Advance X-ray
diffractometer (Bruker AXS) equipped with a SolX detector and running DiffracPlus® software.
The generator voltage and current were set to 40KV and 30mA, respectively. The samples were
scanned from 15° to 40°, 2Θ values with 0.05° ramp at 3 sec/step. Pure components as well as
complexes manufactured using different methods were evaluated.
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6.4.3.5. Scanning Electron microscopy
Scanning Electron Microscope (SEM) was used to study surface morphology of CT,
HPCD and that of complexes. Samples were sputter coated with gold using a Hummer® 6.2
sputtering system (Anatech LTD, Springfield, VA) in a high vacuum evaporator. A JEOL JSM5600 scanning electron microscope operating at an accelerating voltage of 10kV was used for
imaging. Samples were mounted on adhesive carbon pads placed on aluminum stubs prior to
sputter coating.
6.4.4.1. Preparation of Cyclodextrin Complexes
With the data obtained from the Phase solubility studies a 25 mM solution of HPCD was
prepared in deionized water and allowed to equilibrate with excess drug at 25ºC at 75rpm for 7
days. A clear solution thus formed was then freeze dried to obtain the CT: HPCD complex which
was utilized to prepare gel formulations.
6.4.4.2. Formulation of Gel
The gel was prepared by dissolving HPMC in double distilled water to achieve a targeted
concentration of 1%. The gel was allowed to swell overnight and the swollen matrix was used to
formulate CT and CT- HPCD complex gels, Gel A and Gel B respectively. A targeted drug
concentration of 10% CT was used for both the gels. CT due to its low solubility was first
dissolved in a 50:50 mixture of Polyethylene Glycol 400 and Ethanol, and the same was used to
disperse it in the HPMC gel using a mechanical homogenizer. The drug and complex mixtures
were mixed using an UnguatorR EWR electronic mortar and pestle for 5 minutes until whole of
the drug or the complex had blended in. The pH of the gels was adjusted to 5.5 using
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Orthophosphoric acid. Care was taken to avoid formation of any air bubbles in the gels. The so
formed gels were analyzed for content and stored at 4o C till further studies.
The content studies were performed using an HPLC method. Extraction procedure was
optimized and a 50:50 mixture of ACN:Water was used to extract the drug from the gels. Preweighed gel samples were dissolved, sonicated and filtered using a 0.45 micron filter. The
content was established by averaging the results obtained from three replications.
6.4.4.3. In vitro Release studies
In vitro release studies were performed using a SR8 Plus Dissolution apparatus by
Hanson Research. A modified Type II basket apparatus was utilized to perform release studies.
Snakeskin Pleated Dialysis tubing with a cut off molecular weight of 3500 Daltons was used to
contain 5 grams of the gel A and B, and a nylon thread was used to seal the tubes on both ends.
Care was taken to check for any leaks or pores in the dialysis membrane. The gels bags were
then lowered into the basket and fixed to the dissolution apparatus. The release studies were
performed in replicates of three each. The baskets were rotated at 50rpm speed. The dissolution
media consisted of degassed 900ml of pH 5.5 buffer maintained at 37ºC with 1% of Tween 80
added to maintain sink conditions. Samples were collected at intervals of 0.5, 1, 2, 3, 4, 5, 6, 8,
12, 24, 48, 72 and 96 hours and centrifuged. Supernatants were injected into the HPLC directly
and analyzed for percent drug release. The dissolution data was fitted to various release models
to understand the mechanisms involved.

138

6.4.4.4. Antifungal Testing of the Gels
Comparative antifungal evaluation of CT and complexed gels was performed utilizing
cultures of Candida albicans, C.glabrata and C.krusei. 3-5 colonies of each Candida spp. were
suspended in 0.9% sterile saline solution and the colonies formed were estimated by measuring
their optical densities at 630 nm. They were then diluted appropriately to yield 1x106 Colony
Forming Units per ml. (CFU/ml) in a Saboraud Dextrose Broth (SD). 500µl of cell suspensions
of different species of the Candida were then uniformly spread on SD agar petri plates with a
sterile swab, covered and left to dry under the hood. Cylindrical wells of ~75µl were made into
the cultures and equal amount of gels added into them. The cultures where then incubated in an
incubator for 72 hours at 37oC. Appropriate controls were used to assess any antifungal activity
due to the excipients used. Controls cultures included CT, HPβCD, Amphotericin-B and HPMC
- dissolved in DMSO. Zone of inhibition, marked by lack of any fungal growth around the wells,
was used as a measure to compare fungistatic action of the gels.
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6.5. RESULTS AND DISCUSSION
6.5.1. Phase Solubility
The Phase solubility studies were performed using the shake flask method as described
by Higuchi and Connors. The concentration of CT dissolved was plotted against the
concentration of HPCD used. Addition of HPCD resulted in a significant improvement of
solubility of CT. The graph was an AL type curve with the linear plot having a R2 value of
0.99[197]. This suggested formation of a 1:1 inclusion complex of CT and HPCD. The stability
constant obtained from the slope K1:1 was 446.5 M-1 using the Higuchi and Connors equation.

K1:1 =

Equation 6-1.

Where S0 is the intrinsic solubility of CT
For drugs which have very less water solubility, complexation efficiency (CE) is a better
standard of stability due to apparent difficulty in estimating intrinsic solubility values So. The
complexation efficiency obtained was ~0.01 suggesting 1 in 100 molecules undergoes
complexation and can be effectively utilized to estimate the formulations weight in solid oral
dosage forms.
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Figure 6-2. Phase Solubility curve of CT-HPCD in water
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6.5.1.1. Thermal studies
CT is a crystalline drug with a sharp melting point at 145oC – which can be clearly seen
in the DSC spectra as a melting endotherm (Fig. 6-3). The physical mixture had the characteristic
CT peak at 145oC and a broad peak for HPCD due to water loss. Thermogravimetric studies (not
shown) confirmed water loss for HPCD and a degradation above 240oC, suggesting thermal
degradation of HPCD which was also observed in the DSC thermograms. The DSC spectra of
the complex was void of any peaks or broad endotherms signaling formation of a thermodynamic
equilibrium between the drug and the cyclodextrin. CT formed an amorphous complex with
HPCD[198].

Figure 6-3. DSC Thermograms of Complex, HPCD, Physical mixture, Clotrimazole
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6.5.1.2. Fourier Transform Infra-Red spectroscopic analysis (FTIR)
The FTIR spectra of the drug, HPCD, Physical mixture and the complex are presented in
the Figure 6-4. Kneaded product exhibited slight difference in the peaks suggesting
complexation, which was more prominent in complexes manufactured using solvent evaporation.
The peaks corresponding to aromatic C-H stretching above 3000 cm-1 for pure CT disappeared in
the complex. The aromatic ring structure characterized by 1465 cm-1 and 1457 cm-1 wave
numbers, disappeared and reappeared as a single broad peak at 1457 cm-1, similar to an early
reported spectral change observed in complex of CT [198]. The influence on central pi bonded
moiety could be seen by disappearance of peaks at 1327 cm-1, 1305.46 cm-1 and 1262.56 cm-1.
The aromatic regions corresponding to CT, prominent in 600-800 cm-1 region were slightly
influenced in the kneaded product and disappeared completely in the complex indicating
inclusion of the aromatic ring in the cavity of the HPCD and possible hydrogen bonding[188].
C=N and C=C stretching vibrations were observed at 1650 and 1450 cm-1, C-Cl stretching at 750
cm-1 in pure CT, disappeared in the complex suggesting the involvement of aromatic ring ‘A’
and ‘B’ in the complexation process. Similar results were observed in the NMR spectra.
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Figure 6-4. FTIR spectra of puree HPCD, Drug, Physical mixture and Complex
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6.5.1.3. Nuclear Magnetic Resonance Spectroscopic analysis
Continuous variation method was employed to establish the stoichiometry of the complex
using NMR. DMSO Solutions with increasing mole fraction of CT in HPCD were utilized to
generate NMR spectra. However, because of complex mixtures of modified CD and there
isomeric forms, assignment could not be performed for all the protons and only those protons
that exhibited the maximum deviation have been reported. As suggested in the Figure 6-5, H2,
H4, H8 and H10 protons suggest inclusion of A and B aromatic rings in the CD cavity as these
exhibit maximum deviation. H2 and H4 imidazole protons exhibited an upward shift suggesting
their involvement in forming complexes. Similar observations have been reported by Navarro et
al [199]. These protons correspond to aromatic ring ‘A’ and are similar to observations made
from FTIR analysis. A downward shift for H10 protons was observed possibly due to
interactions with the solvent. Relatively small Δδ values suggest a relatively weak association.

Figure 6- 5. Continuous variance plot of Complexed to un-complexed CT
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6.5.1.4. X-Ray diffraction studies
Powder X-ray diffractions studies were perforemd on pure components as well as
complexes to evaluate changes in crystallinity. Complexes manufactured from various methods
such as kneading, physical mixing and freeze drying were evaluated. Characterisitcs crystalline
peaks corresponding to CT were observed at 18, 21, 23, 25.2 and 28- 2Θ values[200, 201] in
Physical mixtures and pure CT (Fig. 6-5). Freeze dried complexes and to lesser extent, in
kneaded complexes, peaks corresponding to CT were either missing or decreased suggesting
conversion of CT to an amorphous form or possible formation of complexes. A decreased
intensity in physcical mixtures can suggest complexation.
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Figure 6-6. PXRD images of pure drug, HPBCD, Physical Mixture, Freeze dried and
Kneaded complex
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6.5.1.5. Scanning Electron Microscopy (SEM)
SEM studies were performed to study the morphology of components before and after
complexation. HPCD exhibited globular structure and lacked sharp features characteristic of a
crystalline nature. DSC results also suggested an amorphous nature. CT is a crystalline
compound and was characterized by sharp needle like crystals. Complexes formed from freeze
drying process were cubic in nature and exhibited a different structure to either of the
components suggesting formation of a complex.
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Figure 6-7. SEM images of HPCD, CT and Complex
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6.5.2. Dissolution Testing Release Profile
The CT-HPCD, Gel B, exhibited a better release profile compared to pure CT gels. After
92 hours of release the CT released was only 75% compared to a 100% release with the complex
(Fig. 6-8). The increased release can be related to the solubilization effect of the Cyclodextrin.
HPCD assists in the solubilization by incorporating the CT molecule in the Lipophillic cavity of
the CD and imparting a hydrophilic character to the drug molecule.

Table: 6- 1. Release coefficients obtained from various dissolution models

Zero order

First order

Higuchi

Korsemeyer Peppas

Dissolution Constants

Regression

Drug

0.007

0.996

Cmplx

0.011

0.946

Drug

0.013

0.853

Cmplx

0.012

0.716

Drug

0.01

0.968

Cmplx

0.01

0.992

Drug

0.63

0.95

Cmplx

0.62

0.97

The dissolution data was fit various kinetic models to understand the release mechanism
involved. The drug release from Gel A (unmodified CT) followed Zero order kinetics with a
release constant of 0.007. Gel B followed zero order kinetics until first 24 hours then deviated
from zero order. The dissolution data for the complex Gel gave the best fit for the Higuchi model
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for release suggesting a controlled release from HPCD. Gel B with HPCD resulted in a higher
solubility, creating a higher concentration gradient resulting in faster and increased release.
In order to understand the type of diffusion mechanism involved the release was fit to
Korsemeyer Peppas equation. A diffusion release exponent ‘n’ obtained from the Korsemeyer
Peppas equation can be used to understand whether the diffusion is fickian or non fickian. An
‘n’ value of 0.5 confirms a Fickian diffusion and a value between 0.5 to 1 is for a non-fickian or
anomalous diffusion[202]. A diffusional release exponent of 0.6 was obtained for both the gels
confirming anomalous (non-fickian) diffusion of drug. HPMC helped in maintaining a controlled
release for both the drug and complex. The hydrophilic polymer surrounds the drug molecule
and the release occurs when the drug molecule dissolves in the media and diffuses out of the
matrix. The solubilized drug is thus removed from the external layer by the movement of fresh
solvent layer resulting in zero order release. HPCD results in increased solubilization of drug, a
higher concentration gradient and hence faster release.

Figure 6-8. In vitro release studies of Gels from Complexed CT and Pure drug
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6.5.3. Antifungal Testing
The gels were tested for antifungal activity using Candida cultures. Zone of inhibition
(Zi) was utilized as a measure of efficacy of the gels. The antimycotic activity of CT could be
seen by the marked absence of fungal growth due to the fungistatic activity of CT in the Zi.
Amphotericin, HPCD and HPMC gels were utilized as controls to evaluate for antifungal
activity. None was observed. CT and CT-CD complex showed significant absence of any fungal
growth compared to Amphotericin B. A considerable decrease in the growth of Candida spp.
was observed [181]. HPCD resulted in an increased concentration of solubilized CT thus aiding
its fungistatic action.

Figure 6-9. Antifungal activity of CT in pure and complexed form
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6.6. Conclusion
CT formed a 1:1 complex with HPCD which was confirmed by Phase solubility, DSC,
FTIR, XRD, NMR and SEM studies. Complexes exhibited a significant improvement in
solubility and dissolution profiles. Complexed CT gels underwent a complete release in 92 h
whereas gels with un-complexed CT releasing only 60±1.2% in the same amount of time.
Antifungal testing was performed using different species of Candida and the zone of inhibition
was used as measure of efficacy of these gels. Complexed CT exhibited a better fungistatic
activity compared to pure CT.
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